<HTML>
   <HEAD>
      <TITLE></TITLE>
   </HEAD>
   <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
filed with the Securities and Exchange Commission on October&nbsp;24, 2023</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registration
      Statement No. 333-</b></font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNITED
STATES<br>SECURITIES AND EXCHANGE COMMISSION<br>Washington, D.C. 20549</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></font></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b>FORM
      S-8</b></font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REGISTRATION
STATEMENT </b><br><b>UNDER<br>THE SECURITIES ACT OF 1933</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b>TITAN
PHARMACEUTICALS, INC.</b></font> <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br>(Exact Name of Registrant
as Specified in Its Charter)</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <td style="border-bottom: Black 1pt solid; vertical-align: top; width: 49%; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delaware</b></font></TD>
    <td style="padding-bottom: 1pt; width: 2%">&nbsp;</td>
            <td style="border-bottom: Black 1pt solid; vertical-align: top; width: 49%; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>94-3171940</b></font></TD>
         </TR>
      <tr>
            <td style="vertical-align: top; text-align: center">(State
            or Other Jurisdiction of<br>Incorporation or Organization)</td>
    <td style="text-align: center; vertical-align: top">&nbsp;</td>
            <td style="vertical-align: top; text-align: center">(I.R.S.
            Employer<br>
Identification Number)</td></tr>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>400
Oyster Point Blvd., Suite 505</b></font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>South
San Francisco, California 94080</b></font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tel:
(650) 244-4990</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address,
      Including Zip Code, and Telephone Number, Including Area Code, of Registrant&rsquo;s Principal Executive Offices)</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TITAN
PHARMACEUTICALS, INC. 2015 OMNIBUS EQUITY INCENTIVE PLAN</b></font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Full
      Title of Plan)</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Kate
Beebe DeVarney, Ph.D., President and Chief Operating Officer</b></font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Titan
Pharmaceuticals, Inc.</b></font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>400
Oyster Point Blvd., Suite 505</b></font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>South
San Francisco, California 94080</b></font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tel:
(650) 244-4990</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name,
      address, including zip code, and telephone number, including area code, of agent for service)</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>With
      a copy to:</i></font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Kenneth A. Schlesinger, Esq.</b></font> <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Spencer Feldman, Esq.</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Olshan Frome Wolosky LLP</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1325 Avenue of the Americas</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>New York, New York 10019</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(212) 451-2300</b></font></p>


      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
      by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
      company, or an emerging growth company. See the definitions of &ldquo;large accelerated filer,&#8221; &ldquo;accelerated filer,&#8221;
      &ldquo;smaller reporting company&#8221; and &ldquo;emerging growth company&#8221; in Rule&nbsp;12b-2 of the Exchange Act.</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in">&nbsp;</td>
<td style="text-align: left; width: 24%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer </font></td>
<td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</font></td>
                                                                              <td style="text-align: left; width: 25%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer </font></td>
                                                                              <td style="text-align: left; width: 19%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</font></td>
</tr>
<tr style="vertical-align: top; text-align: justify">
    <td>&nbsp;</td>
<td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer </font></td>
<td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</font></td>
                                            <td style="text-align: left">Smaller reporting company</td>
                                            <td style="text-align: left"> &#9746;</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
    <td>&nbsp;</td>
<td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</font></td>
<td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</font></td>
                                                                                                                             <td colspan="2" style="text-align: left">&nbsp;</td>
</tr></table>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
      an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
      complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities
      Act.</font> &#9744;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>



<!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>



<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXPLANATORY
      NOTE</b></font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Titan
      Pharmaceuticals, Inc. (the &ldquo;<b>Company</b>&#8221; or the &ldquo;<b>Registrant</b>&#8221;) is filing this registration statement
      on Form S-8 (this &ldquo;<b>Registration Statement</b>&#8221;) to register an additional 2,492,424 shares (the &ldquo;<b>Additional
      Shares</b>&#8221;) of its common stock, par value $0.001 per share (&ldquo;<b>Common Stock</b>&#8221;), issuable pursuant to the
      terms and in the manner set forth in the Company&rsquo;s Amended and Restated 2015 Omnibus Equity Incentive Plan, (the &ldquo;<b>2015
      Plan</b>&#8221;).</font></P>
      <p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
      stockholders of the Company originally approved the 2015 Plan on August&nbsp;24, 2015 with 7,500,000 shares of Common Stock authorized
      for issuance under the 2015 Plan. On September&nbsp;29, 2015, the Company effected a 1-for-5.5 reverse stock split, following which
      the number of shares of Common Stock authorized for issuance under the 2015 Plan was reduced from 7,500,000 to 1,363,637. In November&nbsp;2015,
      the Company filed a registration statement on Form S-8 (the &ldquo;<b>2015 Form S-8</b>&#8221;) to register the 1,363,637 shares
      authorized under the 2015 Plan.</font></P>
      <p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
      August&nbsp;2, 2016, the stockholders of the Company approved an amendment to the 2015 Plan to increase the number of shares of
      Common Stock authorized for issuance under the 2015 Plan from 1,363,637 to 2,500,000. On August&nbsp;7, 2018, the stockholders
      of the Company approved an amendment to the 2015 Plan to increase the number of shares of Common Stock authorized for issuance
      under the 2015 Plan from 2,500,000 to 3,500,000. On January&nbsp;23, 2019, the stockholders of the Company approved an amendment
      to the 2015 Plan to increase the number of shares of Common Stock authorized for issuance under the 2015 Plan from 3,500,000 to
      10,000,000. Also on January&nbsp;23, 2019, the Company effected a 1-for-6 reverse stock split, following which the number of shares
      of Common Stock authorized for issuance under the 2015 Plan was reduced to from 10,000,000 to 1,666,667.</font></P>
      <p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
      November&nbsp;30, 2020, the Company effected a 1-for-30 reverse stock split, following which the number of shares of Common Stock
      authorized for issuance under the 2015 Plan was reduced from 1,666,667 to 55,556. On January&nbsp;8, 2021, the stockholders of
      the Company approved an amendment to the 2015 Plan to, among other things, increase the number of shares of Common Stock authorized
      for issuance under the 2015 Plan from 55,556 to 1,000,000.</font></P>
      <p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
      a result of the aforementioned amendments to the 2015 Plan and reverse stock splits, as of June&nbsp;28 2023, there were a total of
      1,000,000 shares of Common Stock authorized under the 2015 Plan, of which only 7,576 shares were registered under the 2015 Form S-8,
      and 992,424 shares were not. On June&nbsp;29, 2023, the stockholders of the Company approved an amendment to the 2015 Plan to
      increase the number of shares of Common Stock authorized for issuance under the 2015 Plan from 1,000,000 to 2,500,000. As a result,
      this Registration Statement is registering an additional 2,492,424 shares of Common Stock issuable pursuant to the 2015 Plan. The
      2,492,424 shares of Common Stock being registered on this Registration Statement includes 1,464,541 shares held by certain
      securityholders identified in the section of the Reoffer Prospectus (as defined below) entitled &ldquo;Selling
      Securityholders.&rdquo; Such shares have been previously issued pursuant to the Company&rsquo;s Amended and Restated 2015 Omnibus
      Equity Incentive Plan or may be acquired in connection with stock options granted to the Selling Securityholders.</font></P>
      <p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
      Registration Statement also includes a prospectus (the &ldquo;<b>Reoffer Prospectus</b>&#8221;) prepared in accordance with General
      Instruction C of Form S-8 and in accordance with the requirements of Part I of Form S-3. This Reoffer Prospectus may be used for
      the reoffer and resale of shares of Common Stock on a continuous or delayed basis that may be deemed to be &ldquo;restricted securities&#8221;
      and/or &ldquo;control securities&#8221; within the meaning of the Securities Act of 1933, as amended (the &ldquo;<b>Securities
      Act</b>&#8221;), and the rules and regulations promulgated thereunder, that have previously been issued to certain of our executive
      officers, employees, consultants and directors identified in the Reoffer Prospectus. The number of shares of Common Stock included
      in the Reoffer Prospectus represents shares of Common Stock (i) issued to the selling stockholders pursuant to equity awards or
      (ii) issuable pursuant to stock options granted to the selling stockholders, and does not necessarily represent a present intention
      to sell any or all such shares of Common Stock.</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
      I<br>INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</b></font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <td style="vertical-align: top; width: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
            1.</b></font></TD>
            <td style="vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Plan
            Information.</b></font></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
      Company will provide each recipient of a grant under the 2015 Plan (the &ldquo;<b>Recipients</b>&#8221;) with documents that contain
      information related to the 2015 Plan, and other information including, but not limited to, the disclosure required by Item 1 of
      Form S-8, which information is not required to be and is not being filed as a part of this Registration Statement on Form S-8 (the
      &ldquo;<b>Registration Statement</b>&#8221;) or as prospectuses or prospectus supplements pursuant to Rule&nbsp;424 under the Securities
      Act. The foregoing information and the documents incorporated by reference in response to Item 3 of Part II of this Registration
      Statement, taken together, constitute a prospectus that meets the requirements of Section&nbsp;10(a) of the Securities Act. A Section&nbsp;10(a)
      prospectus will be given to each Recipient who receives shares of Common Stock covered by this Registration Statement, in accordance
      with Rule&nbsp;428(b)(1) under the Securities Act.</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR>
            <td style="vertical-align: top; width: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
            2.</b></font></TD>
            <td style="vertical-align: top"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registrant
            Information and Employee Plan Annual Information.</b></font></TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
      will provide to each Recipient a written statement advising of the availability of documents incorporated by reference in Item
      3 of Part II of this Registration Statement (which documents are incorporated by reference in this Section&nbsp;10(a) prospectus)
      and of documents required to be delivered pursuant to Rule&nbsp;428(b) under the Securities Act without charge and upon written
      or oral request by contacting:</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kate
Beebe DeVarney, Ph.D., President and Chief Operating Officer</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Titan
Pharmaceuticals, Inc.</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">400
Oyster Point Blvd., Suite 505</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">South
      San Francisco, California 94080</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REOFFER
      PROSPECTUS</b></font></P>
      <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="img_001.jpg" alt="" style="height: 86px; width: 250px"></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1,464,541
Shares</b></font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock Issued Under the 2015 Plan and</b></font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain
      Awards Granted Outside of the 2015 Plan</b></font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
      Reoffer Prospectus relates to the public resale, from time to time, of an aggregate of 1,464,541 shares (the &ldquo;<b>Shares</b>&#8221;)
      of our common stock, $0.001 par value per share (the &ldquo;<b>Common Stock</b>&#8221;) by certain securityholders identified herein
      in the section entitled &ldquo;Selling Securityholders.&#8221; Such shares have been previously issued pursuant to the Company&rsquo;s
      Amended and Restated 2015 Omnibus Equity Incentive Plan or may be acquired in connection with stock options granted to the Selling
      Securityholders. You should read this prospectus carefully before you invest in our Common Stock.</font></P>
      <p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
      resales shall take place on The Nasdaq Capital Market, or such other stock market or exchange on which our Common Stock may be
      listed or quoted, in negotiated transactions or otherwise, at market prices prevailing at the time of the sale or at prices otherwise
      negotiated (see &ldquo;Plan of Distribution&#8221; starting on page 6 of this prospectus). We will receive no part of the proceeds
      from sales made under this Reoffer Prospectus. The Selling Securityholders will bear all sales commissions and similar expenses.
      Any other expenses incurred by us in connection with the registration and offering and not borne by the Selling Securityholders
      will be borne by us.</font></P>
      <p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
      Reoffer Prospectus has been prepared for the purposes of registering our shares of Common Stock under the Securities Act to allow
      for future sales by Selling Securityholders on a continuous or delayed basis to the public without restriction. We have not entered
      into any underwriting arrangements in connection with the sale of the shares covered by this Reoffer Prospectus. The Selling Securityholders
      identified in this Reoffer Prospectus, or their pledgees, donees, transferees or other successors-in-interest, may offer the shares
      covered by this Reoffer Prospectus from time to time through public or private transactions at prevailing market prices, at prices
      related to prevailing market prices or at privately negotiated prices.</font></P>
      <p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing
      in our Common Stock involves risks. See &ldquo;Risk Factors&#8221; beginning on page 3 of this Reoffer Prospectus. These are speculative
      securities.</font></P>
      <p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
      Common Stock trades on The Nasdaq Capital Market under the symbol &ldquo;TTNP.&#8221; On October&nbsp;23, 2023, the last reported
      sale price of our Common Stock on The Nasdaq Capital Market was $0.34 per share.</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NEITHER
      THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED
      IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</b></font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
      date of this prospectus is October&nbsp;24, 2023</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
      OF CONTENTS</b></font></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>
      <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 90%"><a href="#a_001"><font style="font-size: 10pt">Cautionary Statement Regarding Forward-Looking Statements</font></a></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 9%; text-align: right"><font style="font-size: 10pt">1</font></td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_002"><font style="font-size: 10pt">Prospectus Summary</font></a></td>
    <td>&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">2</font></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_003"><font style="font-size: 10pt">Risk Factors</font></a></td>
    <td>&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">5</font></td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_004"><font style="font-size: 10pt">Use of Proceeds</font></a></td>
    <td>&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">6</font></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_005"><font style="font-size: 10pt">Selling Securityholders</font></a></td>
    <td>&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">7</font></td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_006"><font style="font-size: 10pt">Plan of Distribution</font></a></td>
    <td>&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">9</font></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_007"><font style="font-size: 10pt">Legal Matters</font></a></td>
    <td>&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">11</font></td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_008"><font style="font-size: 10pt">Experts</font></a></td>
    <td>&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">11</font></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_009"><font style="font-size: 10pt">Disclosure of Commission Position on Indemnification For Securities Act Liabilities</font></a></td>
    <td>&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">11</font></td></tr>
  <tr style="background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_010"><font style="font-size: 10pt">Where You Can Find Additional Information</font></a></td>
    <td>&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">11</font></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_011">Incorporation of Certain Documents by Reference</a></td>
    <td>&nbsp;</td>
    <td style="vertical-align: bottom; text-align: right">12</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>



<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_001"></A><B>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</B></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This prospectus contains &ldquo;forward-looking statements&#8221; that involve substantial risks
         and uncertainties. All statements other than statements of historical facts contained
         in this prospectus, including statements regarding our future results of operations
         and financial position, strategy and plans, and our expectations for future operations,
         are forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended (the &ldquo;Securities Act&#8221;), and Section&nbsp;21E of the Exchange Act. We have attempted to identify forward-looking statements by
         terminology including &ldquo;anticipates,&#8221; &ldquo;believes,&#8221; &ldquo;can,&#8221; &ldquo;continue,&#8221; &ldquo;could,&#8221; &ldquo;estimates,&#8221;
         &ldquo;expects,&#8221; &ldquo;intends,&#8221; &ldquo;may,&#8221; &ldquo;plans,&#8221; &ldquo;potential,&#8221; &ldquo;predicts,&#8221; &ldquo;should,&#8221; or &ldquo;will&#8221;
         or the negative of these terms or other comparable terminology. Although we do not
         make forward looking statements unless we believe we have a reasonable basis for doing
         so, we cannot guarantee their accuracy. Forward-looking statements included or incorporated
         by reference in this prospectus or our other filings with the SEC include, but are
         not necessarily limited to, those relating to uncertainties relating to:</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">our ability to raise capital when needed;</TD>
         </TR>
      </TABLE>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">difficulties or delays in the product development process, including the results of
               preclinical studies or clinical trials;</TD>
         </TR>
      </TABLE>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">financing and strategic agreements and relationships;</TD>
         </TR>
      </TABLE>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">difficulties or delays in the regulatory approval process;</TD>
         </TR>
      </TABLE>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">adverse side effects or inadequate therapeutic efficacy of our drug candidates that
               could slow or prevent product development or commercialization;</TD>
         </TR>
      </TABLE>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">dependence on third-party suppliers;</TD>
         </TR>
      </TABLE>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">uncertainties relating to manufacturing, sales, marketing and distribution of our
               drug candidates that may be successfully developed and approved for commercialization;</TD>
         </TR>
      </TABLE>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">the uncertainty of protection for our patents and other intellectual property or trade
               secrets; and</TD>
         </TR>
      </TABLE>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">competition.</TD>
         </TR>
      </TABLE>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">These statements are only predictions and involve known and unknown risks, uncertainties
         and other factors, including the risks outlined under &ldquo;Risk Factors&#8221; or elsewhere
         in this prospectus, which may cause our or our industry&rsquo;s actual results, levels of activity, performance or achievements expressed or implied
         by these forward-looking statements.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Forward-looking statements should not be read as a guarantee of future performance
         or results, and will not necessarily be accurate indications of the times at, or by
         which, that performance or those results will be achieved. Forward-looking statements
         are based on information available at the time they are made and/or management&rsquo;s good faith belief as of that time with respect to future events, and are subject
         to risks and uncertainties that could cause actual performance or results to differ
         materially from what is expressed in or suggested by the forward-looking statements.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Forward-looking statements speak only as of the date they are made. You should not
         put undue reliance on any forward-looking statements. We assume no obligation to update
         forward-looking statements to reflect actual results, changes in assumptions or changes
         in other factors affecting forward-looking information, except to the extent required
         by U.S. federal securities laws. If we do update one or more forward-looking statements,
         no inference should be drawn that we will make additional updates with respect to
         those or other forward-looking statements. We caution you not to give undue weight
         to such projections, assumptions and estimate.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_002"></A><B>PROSPECTUS SUMMARY</B></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The SEC allows us to &ldquo;incorporate by reference&#8221; certain information that we file with the SEC, which means that we can disclose important
         information to you by referring you to those documents. The information incorporated
         by reference is considered to be part of this prospectus, and information that we
         file later with the SEC will update automatically, supplement and/or supersede the
         information disclosed in this prospectus. Any statement contained in a document incorporated
         or deemed to be incorporated by reference in this prospectus shall be deemed to be
         modified or superseded for purposes of this prospectus to the extent that a statement
         contained in this prospectus or in any other document that also is or is deemed to
         be incorporated by reference in this prospectus modifies or supersedes such statement.
         Any such statement so modified or superseded shall not be deemed, except as so modified
         or superseded, to constitute a part of this prospectus. You should read the following
         summary together with the more detailed information regarding our company, our Common
         Stock and our financial statements and notes to those statements appearing elsewhere
         in this prospectus or incorporated herein by reference.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>Our Company</B></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><B>Overview of our Business</B></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are a pharmaceutical company developing therapeutics utilizing a proprietary long-term drug delivery platform, ProNeura<SUP>&#xae;</SUP>, for the treatment of select chronic diseases for which steady state delivery of
         a drug has the potential to provide an efficacy and/or safety benefit. ProNeura consists
         of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and
         a drug substance. The resulting product is a solid matrix that is designed to be administered
         subdermally in a brief, outpatient procedure and is removed in a similar manner at
         the end of the treatment period.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our first product based on the ProNeura technology is Probuphine&#xae; (buprenorphine implant), which is approved in
         the United States, Canada and the European Union, or EU, for the maintenance treatment
         of opioid use disorder in clinically stable patients taking 8 mg or less a day of
         oral buprenorphine. While Probuphine continues to be commercialized in Canada and
         the EU (as Sixmo&#x2122;) by other companies that have either licensed or acquired the rights
         from us, we discontinued commercialization of the product in the United States during
         the fourth quarter of 2020 to allow us to focus our limited resources on other product
         development programs.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In December&nbsp;2021, we announced our intention to work with our financial advisor to explore strategic
         alternatives to enhance stockholder value, potentially including an acquisition, merger,
         reverse merger, sale of assets, licensing or other business combination transaction.
         In June&nbsp;2022, we implemented a plan to reduce expenses and conserve capital that included a
         company-wide reduction in salaries and a scale back of certain operating expenses
         to enable us to maintain sufficient resources as we pursued potential strategic alternatives.
         In July&nbsp;2022, David E. Lazar and Activist Investing LLC acquired an approximately 25% ownership
         interest in our company, filed a proxy statement and nominated six additional directors,
         each of whom was elected to our board of directors at a special meeting of stockholders
         held on August&nbsp;15, 2022 (the &ldquo;Special Meeting&#8221;). The exploration and evaluation of possible strategic
         alternatives by the Board has continued following the Special Meeting. To date, we
         have no commitments with respect to any such strategic alternatives. Following the
         election of new directors at the Special Meeting, Dr. Marc Rubin was replaced as our
         Executive Chairman and Mr.&nbsp;Lazar assumed the position of Chief Executive Officer. In connection with Dr. Rubin&rsquo;s cessation of employment as Executive Chairman, we agreed to make aggregate severance
         payments to him of approximately $400,000, of which approximately $247,000 had been
         paid as of March&nbsp;31, 2023. In December&nbsp;2022, we implemented additional cost reduction measures including a reduction in our
         workforce. On June&nbsp;21, 2023, Mr.&nbsp;Lazar entered into and completed a Share Transfer Agreement with Choong Choon Hau,
         pursuant to which Mr.&nbsp;Lazar sold all of his beneficial ownership interests in our company (excluding equity
         based compensation) to Mr.&nbsp;Choong.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
</DIV>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July&nbsp;26, 2023, the Company entered into an asset purchase agreement (the &ldquo;Asset Purchase Agreement&#8221;) with Fedson,
         Inc., a Delaware corporation (&ldquo;Fedson&#8221;) for the sale of certain ProNeura assets including
         Titan&rsquo;s portfolio of drug addiction products, in addition to other early development programs
         based on the ProNeura drug delivery technology (the &ldquo;ProNeura Assets&#8221;). The Company&rsquo;s addiction portfolio consists of the Probuphine and Nalmefene implant programs. The
         ProNeura Assets constitute only a portion of Titan&rsquo;s assets. On August&nbsp;25, 2023, the Company entered into an Amendment and Extension Agreement with respect to the Asset Purchase Agreement, pursuant to which Fedson agreed to purchase the ProNeura Assets for a purchase price of $2,000,000, consisting of (i) $500,000 in readily available funds, to be paid in full on the
         Closing Date (the &ldquo;Closing Cash&#8221;), (ii) $500,000 in the form of a promissory note
         due and payable on October&nbsp;1, 2023 (the &ldquo;Cash Note&#8221;) and (iii) $1,000,000 in the form of a promissory note due
         and payable on January&nbsp;1, 2024 (the &ldquo;Escrow Note&#8221;, and together with the Closing Cash and the Cash Note, the
         &ldquo;Closing Consideration&#8221;). On the Closing Date, Fedson delivered to the Company a written guaranty by a principal of Fedson of all of Fedson&rsquo;s obligations under both the Cash Note and Escrow Note. In consideration for an extension of the Closing Date to September&nbsp;1, 2023, Fedson paid the Company an advance of $250,000 against the Closing Consideration. On September&nbsp;29, 2023, and in accordance with the terms of the Cash Note, Fedson paid the Company
         $5,000 to extend the payment date of the Cash Note to November&nbsp;1, 2023.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In August&nbsp;2023, the Company received $500,000 in funding in exchange for the issuance of a convertible promissory
         note for that principal amount to Choong Choon Hau (the &ldquo;Hau Promissory Note&#8221;). Pursuant
         to the Hau Promissory Note, the principal amount will accrue interest at a rate of
         10% per annum and will be payable monthly. All principal and accrued interest shall
         be due and payable on January&nbsp;1, 2024, unless extended as provided. All or part of the Hau Promissory Note can be
         converted into our Common Stock at a conversion price of $0.5712 per share from time to time following the issuance date and ending on the maturity
         date.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September&nbsp;13, 2023, the Company entered into a Securities Purchase Agreement (the &ldquo;Purchase Agreement&#8221;)
         with The Sire Group Ltd. (&ldquo;Sire Group&#8221; or the &ldquo;Investor&#8221;), pursuant to which the Company
         agreed to issue 950,000 shares of Series AA Convertible Preferred Stock, par value
         $0.001 per share to Sire Group at a price of $10.00 per share, for an aggregate purchase price of $9,500,000. The purchase price consisted of (i) $5 million in cash at closing and (ii) $4.5 million in the form of a promissory
         note from Sire Group, personally guaranteed by a principal of Sire Group, due and
         payable on September&nbsp;23, 2023, subject to two 10-day extensions which include additional payments of $50,000
         for each extension. Sire Group remitted the $4.5 million principal under the promissory note on September&nbsp;26, 2023.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
</DIV>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<DIV STYLE="padding: 5pt; border: Black 1pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>The Offering</B></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 27%"><B>Outstanding Common Stock:</B></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; vertical-align: middle; width: 3%">&nbsp;</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 70%">15,016,295 shares of our Common Stock are outstanding as of October&nbsp;24, 2023.</TD>
         </TR>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; vertical-align: middle">&nbsp;</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle">&nbsp;</TD>
         </TR>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><B>Common Stock Offered:</B></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; vertical-align: middle">&nbsp;</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">Up to 1,464,541 shares of Common Stock for sale by the Selling Securityholders (which include our executive officers and directors) for their own account pursuant
               to the 2015 Plan.</TD>
         </TR>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; vertical-align: middle">&nbsp;</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle">&nbsp;</TD>
         </TR>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><B>Selling Securityholders:</B></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; vertical-align: middle">&nbsp;</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">The Selling Securityholders are set forth in the section entitled &ldquo;Selling Securityholders&#8221; of this Reoffer Prospectus on page 4. The amount of securities to be offered or resold by means of the Reoffer Prospectus by the designated Selling Securityholders may not exceed, during any three-month period, the amount specified in Rule&nbsp;144(e).</TD>
         </TR>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; vertical-align: middle">&nbsp;</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle">&nbsp;</TD>
         </TR>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><B>Use of proceeds:</B></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; vertical-align: middle">&nbsp;</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">We will not receive any proceeds from the sale of our Common Stock by the Selling Securityholders. We would, however, receive proceeds upon the exercise of the stock options by those
               who receive options under the 2015 Plan and exercise such options for cash. Any cash proceeds will be used by us for general
               corporate purposes.</TD>
         </TR>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; vertical-align: middle">&nbsp;</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle">&nbsp;</TD>
         </TR>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><B>Risk Factors:</B></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; vertical-align: middle">&nbsp;</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">The securities offered hereby involve a high degree of risk. See &ldquo;Risk Factors.&#8221;</TD>
         </TR>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: middle">&nbsp;</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; vertical-align: middle">&nbsp;</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle">&nbsp;</TD>
         </TR>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><B>Nasdaq Capital Market trading symbol</B></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; vertical-align: middle">&nbsp;</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle">&ldquo;TTNP&#8221;</TD>
         </TR>
      </TABLE>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
</DIV>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_003"></A><B>RISK FACTORS</B></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0; text-align: justify">An investment in our securities involves a high degree of risk. You should carefully consider the risks, uncertainties and assumptions discussed in Item
         1A., &ldquo;Risk Factors&#8221; of our annual report on Form 10-K for the fiscal year ended December&nbsp;31, 2022, in Item 1A., &ldquo;Risk Factors&#8221; of our quarterly reports on Form 10-Q for the
         quarters ended March&nbsp;31, 2023 and June&nbsp;30, 2023, and in other documents that we subsequently file with the SEC that update,
         supplement or supersede such information, which documents are incorporated by reference
         into this Reoffer Prospectus. Additional risks not presently known to us or which we consider immaterial based
         on information currently available to us may also materially adversely affect us.
         If any of the events anticipated by the risks described occur, our results of operations
         and financial condition could be adversely affected, which could result in a decline
         in the market price of our common stock, causing you to lose all or part of your investment.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_004"></A><B>USE OF PROCEEDS</B></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">The shares which may be sold under this Reoffer Prospectus will be sold for the respective accounts of each of the Selling Securityholders listed
         herein (which includes our executive officers and directors). Accordingly, we will
         not realize any proceeds from the sale of the shares of our Common Stock. We will
         receive proceeds from the exercise of the options; however, no assurance can be given
         as to when or if any or all of the options will be exercised. If any options are exercised,
         the proceeds derived therefrom will be used for working capital and general corporate
         purposes. All expenses of the registration of the shares will be paid by us. See &ldquo;Selling
         Securityholders&#8221; and &ldquo;Plan of Distribution.&#8221;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_005"></A><B>SELLING SECURITYHOLDERS</B></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are registering for resale the shares covered by this prospectus to permit the
         Selling Securityholders identified below and their pledgees, donees, transferees and
         other successors-in-interest that receive their securities from a Selling Securityholder
         as a gift, partnership distribution or other non-sale related transfer after the date
         of this prospectus to resell the shares when and as they deem appropriate. The Selling
         Securityholders acquired, or may acquire, these shares from us pursuant to the 2015 Plan. The shares may not be sold or otherwise transferred by the Selling Securityholders
         unless and until the applicable awards vest and are exercised, as applicable, in accordance
         with the terms and conditions of the 2015 Plan.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">The following table sets forth:</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the name of each Selling Securityholder;</td>
</tr></table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">the position(s), office or other material relationship with our company and its predecessors
               or affiliates, over the last three years of each Selling Securityholder;</TD>
         </TR>
      </TABLE>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">the number and percentage of shares of our Common Stock that each Selling Securityholder
               beneficially owned as of October&nbsp;24, 2023 prior to the offering for resale of the shares under this prospectus;</TD>
         </TR>
      </TABLE>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">the number of shares of our Common Stock that may be offered for resale for the account
               of each Selling Securityholder under this prospectus; and</TD>
         </TR>
      </TABLE>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">the number and percentage of shares of our Common Stock to be beneficially owned by
               each Selling Securityholder after the offering of the resale shares (assuming all
               of the offered resale shares are sold by such Selling Securityholder).</TD>
         </TR>
      </TABLE>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Information with respect to beneficial ownership is based upon information obtained
         from the Selling Securityholders. Because the Selling Securityholders may offer all
         or part of the shares of Common Stock, which they own pursuant to the offering contemplated
         by this Reoffer Prospectus, and because its offering is not being underwritten on a firm commitment basis, no
         estimate can be given as to the amount of shares that will be held upon termination
         of this offering.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The number of shares in the column &ldquo;Number of Shares Being Offered&rdquo; represents the shares of our Common Stock that each Selling Securityholder may offer
         under this prospectus (&ldquo;Shares&#8221;). We do not know how long the Selling Securityholders
         will hold the Shares before selling them or how many Shares they will sell. The shares of our Common Stock offered by this prospectus may be offered
         from time to time by the Selling Securityholders listed below. We cannot assure you
         that any of the Selling Securityholders will offer for sale or sell any or all of
         the shares of Common Stock offered by them by this prospectus.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td colspan="6" style="vertical-align: bottom; text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number
of<br>
Shares Beneficially</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Owned Prior
to<br>
Offering (1)</b></p></td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number
of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Shares Being</b></p></td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Number of<br>
Shares Beneficially</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Owned After<br>
Offering (2)</b></p>

</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Securityholders</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Number</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&nbsp;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; padding-bottom: 1pt; vertical-align: bottom; font-weight: bold; text-align: center">Percent&nbsp;(%)</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&nbsp;</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Offered</b></p></td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Number</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&nbsp;</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><b>Percent (%)</b></td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td></tr>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 40%; text-align: left">David E. Lazar (3)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">100,000</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">*</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">100,000</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">-%</td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Kate Beebe DeVarney, Ph.D. (4)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">356,533</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2.3</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">356,533</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-%</td><td style="text-align: left">&nbsp;</td></tr>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Avraham Ben-Tzvi (5)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">175,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1.2</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">175,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-%</td><td style="text-align: left">&nbsp;</td></tr>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Eric Greenberg (6)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">175,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1.2</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">175,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-%</td><td style="text-align: left">&nbsp;</td></tr>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Matthew C. McMurdo (7)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">175,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1.2</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">175,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-%</td><td style="text-align: left">&nbsp;</td></tr>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">David Natan (8)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">175,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1.2</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">175,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-%</td><td style="text-align: left">&nbsp;</td></tr>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Brian Crowley (9)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">133,008</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">*</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">133,008</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-%</td><td style="text-align: left">&nbsp;</td></tr>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Peter L. Chasey (10)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">175,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1.2</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">175,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-%</td><td style="text-align: left">&nbsp;</td></tr>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><B>Total:</B></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,464,541</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></td><TD STYLE="width: 0.35in; text-align: left">*</td><TD STYLE="text-align: justify">Indicates beneficial ownership of less than 1% of the outstanding
Common Stock</td>
</tr></table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.35in">(1)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">The number and percentage of shares beneficially owned is determined in accordance
               with Rule&nbsp;13d-3 of the Securities Exchange Act of 1934, as amended, and the information is not
               necessarily indicative of beneficial ownership for any other purpose. Under such rule,
               beneficial ownership includes any shares as to which the Selling Securityholder has
               sole or shared voting power or investment power and also any shares which the Selling
               Securityholder has the right to acquire within 60 days. Applicable percentage ownership
               is based on 15,016,295 shares of Common Stock outstanding as of October&nbsp;24, 2023.</TD>
         </TR>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top">(2)</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">Assumes that all shares of Common Stock to be offered, as set forth above, are sold
               pursuant to this offering and that no other shares of Common Stock are acquired or
               disposed of by the Selling Securityholders prior to the termination of this offering.
               Because the Selling Securityholders may sell all, some or none of their shares of
               Common Stock or may acquire or dispose of other shares of Common Stock, no reliable
               estimate can be made of the aggregate number of shares of Common Stock that will be
               sold pursuant to this offering or the number or percentage of shares of Common Stock
               that each Selling Securityholder will own upon completion of this offering.</TD>
         </TR>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top">(3)</TD>
            <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top">Mr.&nbsp;Lazar is our Chief Executive
            Officer and our former Chairman of the Board. </TD>
         </TR>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top">(4)</TD>
            <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top">Dr. Beebe DeVarney is our President and Chief Operating Officer and a member of the Board. The shares of Common Stock beneficially owned include 306,553 shares of common stock subject to options exercisable within 60 days of October&nbsp;24, 2023.</TD>
         </TR>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top">(5)</TD>
            <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top">Mr.&nbsp;Ben-Tzvi is a member of the Board. The shares of Common Stock beneficially owned include 125,000 shares of common stock subject to options exercisable within 60 days of October&nbsp;24, 2023.</TD>
         </TR>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top">(6)</TD>
            <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top">Mr.&nbsp;Greenberg is a member of the Board. The shares of Common Stock beneficially owned include 125,000 shares of common stock subject to options exercisable within 60 days of October&nbsp;24, 2023.</TD>
         </TR>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top">(7)</TD>
            <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top">Mr.&nbsp;McMurdo is a member of the Board. The shares of Common Stock beneficially owned include 125,000 shares of common stock subject to options exercisable within 60 days of October&nbsp;24, 2023.</TD>
         </TR>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top">(8)</TD>
            <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top">Mr.&nbsp;Natan is a member of the Board. The shares of Common Stock beneficially owned include 125,000 shares of common stock subject to options exercisable within 60 days of October&nbsp;24, 2023.</TD>
         </TR>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top">(9)</TD>
            <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top">Mr.&nbsp;Crowley is our Sr. Vice President, Finance. The shares of Common Stock beneficially
               owned include 83,008 shares of common stock subject to options exercisable within 60 days of October&nbsp;24, 2023.</TD>
         </TR>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top">(10)</TD>
            <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top">Mr.&nbsp;Chasey is a former member of the Board. The shares of Common Stock beneficially owned include 125,000 shares of common stock subject to options exercisable within 60 days of October&nbsp;24, 2023.</TD>
         </TR>
      </TABLE>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_006"></A><B>PLAN OF DISTRIBUTION</B></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are registering the Shares covered by this prospectus to permit the Selling Stockholders
         to conduct public secondary trading of these Shares from time to time after the date
         of this prospectus. We will not receive any of the proceeds of the sale of the Shares
         offered by this prospectus. The aggregate proceeds to the Selling Stockholders from
         the sale of the Shares will be the purchase price of the Shares less any discounts
         and commissions. We will not pay any brokers&rsquo; or underwriters&rsquo; discounts and commissions in connection with the registration and sale of the Shares
         covered by this prospectus. The Selling Stockholders reserve the right to accept and,
         together with their respective agents, to reject, any proposed purchases of Shares
         to be made directly or through agents.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Shares offered by this prospectus may be sold from time to time to purchasers:</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">directly by the Selling Stockholders, or</TD>
         </TR>
      </TABLE>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">through underwriters, broker-dealers or agents, who may receive compensation in the
               form of discounts, commissions or agent&rsquo;s commissions from the Selling Stockholders or the purchasers of the Shares.</TD>
         </TR>
      </TABLE>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any underwriters, broker-dealers or agents who participate in the sale or distribution
         of the Shares may be deemed to be &ldquo;underwriters&#8221; within the meaning of the Securities
         Act. As a result, any discounts, commissions or concessions received by any such broker-dealer
         or agents who are deemed to be underwriters will be deemed to be underwriting discounts
         and commissions under the Securities Act. Underwriters are subject to the prospectus
         delivery requirements of the Securities Act and may be subject to certain statutory
         liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended
         (the &ldquo;Exchange Act&#8221;). We will make copies of this prospectus available to the Selling
         Stockholders for the purpose of satisfying the prospectus delivery requirements of
         the Securities Act. To our knowledge, there are currently no plans, arrangements or
         understandings between the Selling Stockholders and any underwriter, broker-dealer
         or agent regarding the sale of the Shares by the Selling Stockholders.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Shares may be sold in one or more transactions at:</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">fixed prices;</TD>
         </TR>
      </TABLE>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">prevailing market prices at the time of sale;</TD>
         </TR>
      </TABLE>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">prices related to such prevailing market prices;</TD>
         </TR>
      </TABLE>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">varying prices determined at the time of sale; or</TD>
         </TR>
      </TABLE>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">negotiated prices.</TD>
         </TR>
      </TABLE>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">These sales may be effected in one or more transactions:</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">on any national securities exchange or quotation service on which the Shares may be
               listed or quoted at the time of sale, including the The Nasdaq Capital Market;</TD>
         </TR>
      </TABLE>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">in the over-the-counter market;</TD>
         </TR>
      </TABLE>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">in transactions otherwise than on such exchanges or services or in the over-the-counter
               market;</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">any other method permitted by applicable law; or</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <TR STYLE="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; text-align: right; vertical-align: top"></TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left; text-indent: 0in; vertical-align: top">&#9679;</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; text-indent: 0in">through any combination of the foregoing.</TD>
         </TR>
      </TABLE>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">These transactions may include block transactions or crosses. Crosses are transactions
         in which the same broker acts as an agent on both sides of the trade.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At the time a particular offering of the Shares is made, a prospectus supplement,
         if required, will be distributed, which will set forth the name of the Selling Stockholders,
         the aggregate amount of Shares being offered and the terms of the offering, including,
         to the extent required, (1) the name or names of any underwriters, broker-dealers
         or agents, (2) any discounts, commissions and other terms constituting compensation
         from the Selling Stockholders and (3) any discounts, commissions or concessions allowed
         or reallowed to be paid to broker-dealers.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Selling Stockholders will act independently of us in making decisions with respect
         to the timing, manner, and size of each resale or other transfer. There can be no
         assurance that the Selling Stockholders will sell any or all of the Shares under this
         prospectus. Further, we cannot assure you that the Selling Stockholders will not transfer,
         distribute, devise or gift the Shares by other means not described in this prospectus.
         In addition, any Shares covered by this prospectus that qualify for sale under Rule&nbsp;144 of the Securities Act may be sold under Rule&nbsp;144 rather than under this prospectus. The Shares may be sold in some states only through
         registered or licensed brokers or dealers. In addition, in some states the Shares
         may not be sold unless they have been registered or qualified for sale or an exemption
         from registration or qualification is available and complied with.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Selling Stockholders and any other person participating in the sale of the Shares
         will be subject to the Exchange Act. The Exchange Act rules include, without limitation,
         Regulation M, which may limit the timing of purchases and sales of any of the Shares
         by the Selling Stockholders and any other person. In addition, Regulation M may restrict
         the ability of any person engaged in the distribution of the Shares to engage in market-making
         activities with respect to the particular Shares being distributed. This may affect
         the marketability of the Shares and the ability of any person or entity to engage
         in market-making activities with respect to the Shares.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Selling Stockholders may indemnify any broker or underwriter that participates
         in transactions involving the sale of the Shares against certain liabilities, including
         liabilities arising under the Securities Act.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_007"></A><B>LEGAL MATTERS</B></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">The validity of the issuance of the securities offered by this prospectus will be
         passed upon for us by Olshan Frome Wolosky LLP, New York, New York.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_008"></A><B>EXPERTS</B></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">The financial statements of Titan Pharmaceuticals, Inc. included in our annual report
         on Form 10-K for the fiscal years ended December&nbsp;31, 2022 and 2021 have been audited by WithumSmith+Brown, PC, independent registered public
         accountants, as set forth in their reports thereon, included therein, and incorporated
         herein by reference in this prospectus, which report includes an explanatory paragraph about the existence of substantial
         doubt concerning the Company&rsquo;s ability to continue as a going concern, and elsewhere in the registration statement. Such financial statements are incorporated
         herein by reference in reliance upon such reports given on the authority of said firm
         as experts in accounting and auditing.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_009"></A><b>DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION</b></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FOR SECURITIES ACT LIABILITIES</B></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">Insofar as indemnification for liabilities arising under the Securities Act may be
         permitted to directors, officers or persons controlling the registrant, the registrant
         has been informed that in the opinion of the Commission such indemnification is against
         public policy as expressed in the Securities Act and is therefore unenforceable.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_010"></A><B>WHERE YOU CAN FIND MORE INFORMATION</B></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">We file annual reports, quarterly and
      current reports, proxy statements and other information with the SEC. The SEC maintains an Internet website that contains reports,
      proxy and information statements, and other information regarding issuers that file electronically with the SEC at <u>www.sec.gov</u>.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">We maintain an Internet website at www.titanpharm.com. All of our reports filed with
         the SEC (including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current
         Reports on Form 8-K and proxy statements) are accessible through the Investor Relations
         section of our website, free of charge, as soon as reasonably practicable after electronic
         filing. The reference to our website in this prospectus is an inactive textual reference
         only and is not a hyperlink. The contents of our website are not part of this prospectus,
         and you should not consider the contents of our website in making an investment decision
         with respect to our securities.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PART II</b></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</B></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><A NAME="a_011"></A>Item 3. Incorporation of Documents by Reference</B></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">The following documents previously filed with the Commission by the Company are incorporated by reference herein:</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in">&nbsp;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">(1)</TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; padding-left: -0.25in">The Annual Report on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/910267/000182912623002504/titanpharma_10k.htm">Form 10-K</A> for the year ended December&nbsp;31, 2022, filed with the Commission on March&nbsp;31, 2023;</TD>
         </TR>
         <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&nbsp;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; padding-left: -0.25in">&nbsp;</td></tr>
         <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&nbsp;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">(2)</TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; padding-left: -0.25in">The Quarterly Reports on Form 10-Q (i) for the fiscal quarter ended March&nbsp;31, 2023, filed with the Commission on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/910267/000182912623003437/titanpharma_10q.htm">May&nbsp;15, 2023</A> and (ii) for the fiscal quarter ended June&nbsp;30, 2023, filed with the Commission on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/910267/000182912623005424/titanpharma_10q.htm">August&nbsp;14, 2023</A>; </TD>
         </TR>
         <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&nbsp;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; padding-left: -0.25in">&nbsp;</td></tr>
         <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&nbsp;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">(3)</TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; padding-left: -0.25in">The Current Reports on Form 8-K (other than information furnished rather than filed) filed with the Commission on <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/910267/000182912623000571/titanpharma_8k.htm">January&nbsp;6, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/910267/000182912623001405/titanpharma_8k.htm">February&nbsp;9, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/910267/000182912623001871/titanpharma_8k.htm">March&nbsp;3, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/910267/000182912623002186/titanpharma_8k.htm">March&nbsp;22, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/910267/000182912623002648/titanpharma_8k.htm">April&nbsp;11, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/910267/000182912623003950/titanpharma_8k.htm">June&nbsp;6, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/910267/000182912623004483/titanpharma_8k.htm">June&nbsp;29, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/910267/000182912623004586/titanpharmaceuticals_8k.htm">July&nbsp;7, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/910267/000182912623004963/titanpharma_8k.htm">July&nbsp;28, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/910267/000182912623005752/titanpharma_8k.htm">August&nbsp;30, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/910267/000182912623006020/titanpharma_8k.htm">September&nbsp;8, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/910267/000182912623006161/titanpharma_8k.htm">September&nbsp;18, 2023</A>, as amended, and <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/910267/000182912623006660/titanpharma_8k.htm">October&nbsp;16, 2023</A>; and</TD>
         </TR>
         <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&nbsp;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; padding-left: -0.25in">&nbsp;</td></tr>
         <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&nbsp;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">(4)</TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; padding-left: -0.25in">The Definitive Proxy Statement on <A HREF="https://www.sec.gov/Archives/edgar/data/910267/000182912623003608/titanpharma_defa14a.htm">Schedule&nbsp;14A</A>, filed with the SEC on May&nbsp;19, 2023; and</TD>
         </TR>
         <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&nbsp;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; padding-left: -0.25in">&nbsp;</td></tr>
         <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&nbsp;</td>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">(5)</TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; padding-left: -0.25in">The description of common stock contained in Forms 8 and 8-A previously filed with the Commission and any amendments or reports filed for the purpose of updating such description.</TD>
         </TR>
      </TABLE>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">All documents filed by the Company pursuant to Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934 (other than documents
         or information deemed to have been &ldquo;furnished&#8221; and not &ldquo;filed&#8221;) after the date hereof
         and before the filing of a post-effective amendment that indicates that all securities
         offered hereby have been sold or that deregisters all securities then remaining unsold
         shall be deemed to be incorporated by reference herein and to be part hereof from
         the date of filing those documents. Any statement contained in any document incorporated
         or deemed to be incorporated by reference herein shall be deemed to be modified or
         superseded for purposes of this registration statement to the extent that a statement
         contained herein or in any subsequently filed document which is or is deemed to be
         incorporated by reference herein modifies or supersedes the statement. Any statement
         so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 4. Description of Securities.</B></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">Not applicable.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 5. Interests of Named Experts and Counsel.</B></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">None.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 6. Indemnification of Directors and Officers</B>.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Amended and Restated Bylaws</B></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to our bylaws, our directors and officers will be indemnified to the fullest
         extent allowed under the laws of the State of Delaware for their actions in their
         capacity as our directors and officers.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We must indemnify any person made a party to any threatened, pending, or completed
         action, suit, or proceeding, whether civil, criminal, administrative, or investigative
         (&ldquo;Proceeding&#8221;) by reason of the fact that he is or was a director, against judgments,
         penalties, fines, settlements and reasonable expenses (including attorney&rsquo;s fees) (&ldquo;Expenses&#8221;) actually and reasonably incurred by him in connection with such
         Proceeding if: (a) he conducted himself in good faith, and: (i) in the case of conduct
         in his own official capacity with us, he reasonably believed his conduct to be in
         our best interests, or (ii) in all other cases, he reasonably believes his conduct
         to be at least not opposed to our best interests; and (b) in the case of any criminal
         Proceeding, he had no reasonable cause to believe his conduct was unlawful. We must
         indemnify any person made a party to any Proceeding by or in the right of us, by reason
         of the fact that he is or was a director, against reasonable expenses actually incurred
         by him in connection with such proceeding if he conducted himself in good faith, and:
         (a) in the case of conduct in his official capacity with us, he reasonably believed
         his conduct to be in our best interests; or (b) in all other cases, he reasonably
         believed his conduct to be at least not opposed to our best interests; provided that
         no such indemnification may be made in respect of any proceeding in which such person
         shall have been adjudged to be liable to us. No indemnification will be made by unless
         authorized in the specific case after a determination that indemnification of the
         director is permissible in the circumstances because he has met the applicable standard
         of conduct. Reasonable expenses incurred by a director who is party to a proceeding
         may be paid or reimbursed by us in advance of the final disposition of such Proceeding
         in certain cases.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have the power to purchase and maintain insurance on behalf of any person who is
         or was our director, officer, employee, or agent or is or was serving at our request
         as an officer, employee or agent of another corporation, partnership, joint venture,
         trust, other enterprise, or employee benefit plan against any liability asserted against
         him and incurred by him in any such capacity or arising out of his status as such,
         whether or not we would have the power to indemnify him against such liability under
         the provisions of the amended and restated bylaws.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Delaware Law</B></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section&nbsp;145 of the Delaware General Corporation Law provides that a Delaware corporation may
         indemnify any persons who are, or are threatened to be made, parties to any threatened,
         pending or completed action, suit or proceeding, whether civil, criminal, administrative
         or investigative (other than an action by or in the right of such corporation), by
         reason of the fact that such person was an officer, director, employee or agent of
         such corporation, or is or was serving at the request of such person as an officer,
         director, employee or agent of another corporation or enterprise. The indemnity may
         include expenses (including attorneys&rsquo; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred
         by such person in connection with such action, suit or proceeding, provided that such
         person acted in good faith and in a manner he or she reasonably believed to be in
         or not opposed to the corporation&rsquo;s best interests and, with respect to any criminal action or proceeding, had no reasonable
         cause to believe that his or her conduct was illegal. A Delaware corporation may indemnify
         any persons who are, or are threatened to be made, a party to any threatened, pending
         or completed action or suit by or in the right of the corporation by reason of the
         fact that such person was a director, officer, employee or agent of such corporation,
         or is or was serving at the request of such corporation as a director, officer, employee
         or agent of another corporation or enterprise. The indemnity may include expenses
         (including attorneys&rsquo; fees) actually and reasonably incurred by such person in connection with the defense
         or settlement of such action or suit provided such person acted in good faith and
         in a manner he or she reasonably believed to be in or not opposed to the corporation&rsquo;s best interests except that no indemnification is permitted without judicial approval
         if the officer or director is adjudged to be liable to the corporation. Where an officer
         or director is successful on the merits or otherwise in the defense of any action
         referred to above, the corporation must indemnify him or her against the expenses
         which such officer or director has actually and reasonably incurred. Our amended and
         restated certificate of incorporation and amended and restated bylaws provide for
         the indemnification of our directors and officers to the fullest extent permitted
         under the Delaware General Corporation Law.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section&nbsp;102(b)(7) of the Delaware General Corporation Law permits a corporation to provide
         in its certificate of incorporation that a director of the corporation shall not be
         personally liable to the corporation or its stockholders for monetary damages for
         breach of fiduciary duties as a director, except for liability for any:</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in">&nbsp;</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">&#9679;</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">transaction from which the director derives an improper personal benefit;</TD>
         </TR>
      </TABLE>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in">&nbsp;</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">&#9679;</TD>
            <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">act or omission not in good faith or that involves intentional misconduct or a knowing
               violation of law;</TD>
         </TR>
      </TABLE>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in">&nbsp;</TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">&#9679;</TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">unlawful payment of dividends or redemption of shares; or</TD>
         </TR>
      </TABLE>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in">&nbsp;</TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">&#9679;</TD>
            <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">breach of a director&rsquo;s duty of loyalty to the corporation or its stockholders.</TD>
         </TR>
      </TABLE>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our amended and restated certificate of incorporation and amended and restated bylaws
         include such a provision. Expenses incurred by any officer or director in defending
         any such action, suit or proceeding in advance of its final disposition shall be paid
         by us upon delivery to us of an undertaking, by or on behalf of such director or officer,
         to repay all amounts so advanced if it shall ultimately be determined that such director
         or officer is not entitled to be indemnified by us.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Section&nbsp;174 of the Delaware General Corporation Law provides, among other things, that a director
         who willfully or negligently approves of an unlawful payment of dividends or an unlawful
         stock purchase or redemption may be held liable for such actions. A director who was
         either absent when the unlawful actions were approved, or dissented at the time, may
         avoid liability by causing his or her dissent to such actions to be entered in the
         books containing minutes of the meetings of the board of directors at the time such
         action occurred or immediately after such absent director receives notice of the unlawful
         acts.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Indemnification Agreements</B></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As permitted by the Delaware General Corporation Law, we have entered, and intend
         to continue to enter, into separate indemnification agreements with each of our directors
         and executive officers, that require us to indemnify such persons against any and
         all expenses (including attorneys&rsquo; fees), witness fees, damages, judgments, fines, settlements and other amounts incurred
         (including expenses of a derivative action) in connection with any action, suit or
         proceeding, whether actual or threatened, to which any such person may be made a party
         by reason of the fact that such person is or was a director, an officer or an employee
         of us or any of our affiliated enterprises, provided that such person acted in good
         faith and in a manner such person reasonably believed to be in or not opposed to our
         best interests and, with respect to any criminal proceeding,</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 7. Exemption from Registration Claimed</B>.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">Not applicable.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 8. Exhibits.</B></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; text-align: left"><b>Exhibit
    No.</b></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; width: 1%; vertical-align: bottom">&nbsp;</td>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 90%; text-align: left"><b>Description
    of Exhibit</b></td>
    </tr>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">3.1.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><a href="https://www.sec.gov/Archives/edgar/data/910267/000119312510006562/dex31.htm">Amended and Restated Certificate of Incorporation of the Registrant, as amended (incorporated by reference to Exhibit 3.1 to the Company&rsquo;s Registration Statement on Form 10 filed on January 14, 2010)</a>.</td></tr>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">3.1.2</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><a href="https://www.sec.gov/Archives/edgar/data/910267/000114420415056647/v421014_ex3-1.htm">Certificate of Amendment to the Restated Certificate of Incorporation dated September 24, 2015 (incorporated by reference to Exhibit 3.1 to the Company&rsquo;s <font>Current Report on Form 8-K filed on September 28, 2015</font>).</a></td></tr>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">3.1.3</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><a href="https://www.sec.gov/Archives/edgar/data/910267/000114420419002680/tv511477_ex3-1.htm">Certificate of Amendment to the Restated Certificate of Incorporation dated January 23, 2019 (incorporated by reference to Exhibit 3.1 to the Company&rsquo;s Current Report on Form 8-K dated January 25, 2019.</a></td></tr>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">3.1.4</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><a href="https://www.sec.gov/Archives/edgar/data/910267/000110465920131098/tm2037359d1_ex3-1.htm">Certificate of Amendment to the Restated Certificate of Incorporation dated November 30, 2020 (incorporated by reference to Exhibit 3.1 to the Company&rsquo;s <font>Current Report on Form&nbsp;8-K dated December&nbsp;1, 2020</font>).</a></td></tr>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">3.2</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><a href="https://www.sec.gov/Archives/edgar/data/910267/000114420417054170/tv477697_ex3-3.htm">By-laws of the Registrant (incorporated by reference to Exhibit 3.3 to the Company&rsquo;s <font>Registration Statement on Form S-3 (File No. 333-221126))</font></a><font>.</font></td></tr>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">3.3</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><a href="https://www.sec.gov/Archives/edgar/data/910267/000110465921154063/tm2136487d2_ex3-1.htm">Amendment to the By-laws of the Registrant dated December 29, 2021 (incorporated by reference to Exhibit 3.1 to the Company&rsquo;s <font>Current Report on Form&nbsp;8-K dated December&nbsp;29, 2021</font>).</a></td></tr>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">3.4</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><a href="https://www.sec.gov/Archives/edgar/data/910267/000110465922077431/tm2220416d1_ex3-1.htm">Amendment to the By-laws of the Registrant dated July 5, 2022 (incorporated by reference to Exhibit 3.1 to the Company&rsquo;s <font>Current Report on Form&nbsp;8-K dated July 5, 2022)</font></a><font>.</font></td></tr>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">5.1*</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><A HREF="titanpharma_ex5-1.htm">Opinion of Olshan Frome Wolosky LLP, counsel to the Company.</A></td></tr>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">10.14</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><a href="https://www.sec.gov/Archives/edgar/data/910267/000182912622017040/titanpharma_ex10-1.htm">Form of Stock Option Agreement (incorporated by reference to Exhibit 10.1 to the Company&rsquo;s <font>Current Report on Form&nbsp;8-K dated September 21, 2022</font>).</a></td></tr>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">10.15</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><a href="https://www.sec.gov/Archives/edgar/data/910267/000182912622019258/titanpharma_ex10-2.htm">Fifth Amended and Restated 2015 Omnibus Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company&rsquo;s <font>Quarterly Report on Form 10-Q for the period ended September 30, 2022</font>).</a></td></tr>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">23.1*</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><A HREF="titanpharma_ex23-1.htm">Consent of WithumSmith+Brown, P.C., independent registered public accounting firm.</A></td></tr>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">23.2*</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><A HREF="titanpharma_ex5-1.htm">Consent of Olshan Frome Wolosky LLP (included in Exhibit 5.1).</A></td></tr>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">24.1*</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><A HREF="#poa">Powers of Attorney (included on the signature pages to this Registration Statement).</A></td></tr>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in">107*</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><A HREF="titanpharma_ex107.htm">Filing Fee Table.</A></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Filed herewith.</td>
</tr></table>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 9. Undertakings</B></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> (a) The undersigned registrant hereby undertakes:</p>


      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">(1) To file, during any period in which offers or sales are being made, a post-effective
         amendment to this registration statement:</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(i) To include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act of 1933;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(ii) To reflect in the prospectus any facts or events arising after the effective
         date of the registration statement (or the most recent post-effective amendment thereof)
         which, individually or in the aggregate, represent a fundamental change in the information
         set forth in the registration statement. Notwithstanding the foregoing, any increase
         or decrease in volume of securities offered (if the total dollar value of securities
         offered would not exceed that which was registered) and any deviation from the low
         or high end of the estimated maximum offering range may be reflected in the form of
         prospectus filed with the Commission pursuant to Rule&nbsp;424(b) if, in the aggregate, the changes in volume and price represent no more than
         a 20 percent change in the maximum aggregate offering price set forth in the &ldquo;Calculation
         of Registration Fee&#8221; table in the effective registration statement; and</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(iii) To include any material information with respect to the plan of distribution
         not previously disclosed in the registration statement or any material change to such
         information in this registration statement.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Provided, however</I>, that the undertakings set forth in paragraphs (a)(1)(i) and (a)(1)(ii) above do
         not apply if the information required to be included in a post-effective amendment
         by those paragraphs is contained in reports filed with or furnished to the Commission
         by the registrant pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in
         the registration statement.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">(2) That, for the purpose of determining any liability under the Securities Act of
         1933, each such post-effective amendment shall deemed to be a new registration statement
         relating to the securities offered therein, and the offering of such securities at
         that time shall be deemed to be the initial bona fide offering thereof.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">(3) To remove from registration by means of a post-effective amendment any of the
         securities being registered which remain unsold at the termination of the offering.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(b) The undersigned registrant hereby undertakes
      that for the purpose of determining any liability under the Securities Act of 1933, each filing of the registrant&rsquo;s annual
      report pursuant to Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an
      employee benefit plan&rsquo;s annual report pursuant to Section&nbsp;15(d) of the Securities Exchange Act of 1934) that is
      incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the
      securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
      thereof.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(c) Insofar as indemnification for liabilities
      arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant
      to the foregoing provisions or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification
      is against public policy as expressed in the Securities Act of 1933 and is therefore unenforceable. In the event that a claim for
      indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director,
      officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such
      director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the
      opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
      question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933, and will be
      governed by the final adjudication of such issue.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>



<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of
         the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Dubai, United Arab Emirates on the 24<SUP>th</SUP> day of October, 2023.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; background-color: #FFFFFF">&nbsp;</TD>
            <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; background-color: #FFFFFF"><B>TITAN PHARMACEUTICALS, INC.</B> </TD>
         </TR>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; background-color: #FFFFFF">&nbsp;</TD>
            <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; background-color: #FFFFFF">&nbsp;</TD>
         </TR>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; background-color: #FFFFFF">&nbsp;</TD>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; background-color: #FFFFFF">By:</TD>
            <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; background-color: #FFFFFF">/s/ David E. Lazar</TD>
         </TR>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 50%; background-color: #FFFFFF">&nbsp;</TD>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 4%; background-color: #FFFFFF">&nbsp;</TD>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 5%; background-color: #FFFFFF">Name:</TD>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 41%; background-color: #FFFFFF">David E. Lazar</TD>
         </TR>
         <tr style="font: 10pt Times New Roman, Times, Serif">
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; background-color: #FFFFFF">&nbsp;</TD>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; background-color: #FFFFFF">&nbsp;</TD>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; background-color: #FFFFFF">Title:</TD>
            <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; background-color: #FFFFFF">Chief Executive Officer</TD>
         </TR>
      </TABLE>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="poa"></A>POWER OF ATTORNEY</B></P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">KNOW ALL PERSONS BY THESE PRESENTS, each director and officer whose signature appears
         below constitutes and appoints each of David E. Lazar and Katherine Beebe DeVarney, Ph.D. his true and lawful attorney-in-fact and agent, with full power of substitution and
         re-substitution, to sign in any and all capacities any and all amendments or post-effective
         amendments to this registration statement, and to sign any and all additional registration
         statements relating to the same offering of securities of the Registration Statement
         that are filed pursuant to Rule&nbsp;462(b) of the Securities Act, and to file the same with all exhibits thereto and other
         documents in connection therewith with the Securities and Exchange Commission, granting
         such attorney-in-fact and agent full power and authority to do all such other acts
         and execute all such other documents as he may deem necessary or desirable in connection
         with the foregoing, as fully as the undersigned may or could do in person, hereby
         ratifying and confirming all that such attorney-in-fact and agent may lawfully do
         or cause to be done by virtue hereof.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements of the Securities Act of 1933, this registration statement
         has been signed by the following persons in the capacities and on the dates indicated.</P>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 40%"><B>Name</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: center; width: 2%"><B>&nbsp;</B></TD>
  <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 40%"><B>Title</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: center; width: 2%"><B>&nbsp;</B></TD>
  <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 16%"><B>Date</B></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center">/s/ David E. Lazar</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Chief Executive Officer</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">October 24, 2023</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">David Lazar</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Principal Executive Officer</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Chairman of the Board of Directors</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Seow Gim Shen</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center">/s/ Katherine Beebe DeVarney, Ph.D.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">President, Chief Operating Officer and Director</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">October 24, 2023</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Katherine Beebe DeVarney, Ph.D.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center">/s/ Avraham Ben-Tzvi, Adv.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Director</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">October 24, 2023</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Avraham Ben-Tzvi, Adv.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Director</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Brynner Chiam</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center">/s/ Eric Greenberg</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Director</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">October 24, 2023</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Eric Greenberg</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center">/s/ Matthew C. McMurdo, Esq.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Director</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">October 24, 2023</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Matthew C. McMurdo, Esq.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center">/s/ David Natan</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Director</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">October 24, 2023</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">David Natan</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center">/s/ Brian Crowley</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Vice President, Finance (Principal Accounting Officer)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">October 24, 2023</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">Brian Crowley</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->


   </BODY>
</HTML>
[{"type": "S-8", "sequence": "1", "filename": "titanpharma_s8.htm", "description": "S-8", "secsgml_size_bytes": 199579}]
{"company-data": {"conformed-name": "TITAN PHARMACEUTICALS INC", "cik": "0000910267", "assigned-sic": "2836", "irs-number": "943171940", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-275153", "film-number": "231343482"}, "business-address": {"street1": "400 OYSTER POINT BLVD", "street2": "SUITE 505", "city": "SAN FRANCISCO", "state": "CA", "zip": "94080", "phone": "6502444990"}, "mail-address": {"street1": "400 OYSTER POINT BLVD", "street2": "SUITE 505", "city": "SAN FRANCISCO", "state": "CA", "zip": "94080"}}
As
filed with the Securities and Exchange Commission on October 24, 2023
Registration
      Statement No. 333-
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
      S-8
REGISTRATION
STATEMENT
UNDER
THE SECURITIES ACT OF 1933
TITAN
PHARMACEUTICALS, INC.
(Exact Name of Registrant
as Specified in Its Charter)
Delaware
94-3171940
(State
            or Other Jurisdiction of
Incorporation or Organization)
(I.R.S.
            Employer
Identification Number)
400
Oyster Point Blvd., Suite 505
South
San Francisco, California 94080
Tel:
(650) 244-4990
(Address,
      Including Zip Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices)
TITAN
PHARMACEUTICALS, INC. 2015 OMNIBUS EQUITY INCENTIVE PLAN
(Full
      Title of Plan)
Kate
Beebe DeVarney, Ph.D., President and Chief Operating Officer
Titan
Pharmaceuticals, Inc.
400
Oyster Point Blvd., Suite 505
South
San Francisco, California 94080
Tel:
(650) 244-4990
(Name,
      address, including zip code, and telephone number, including area code, of agent for service)
With
      a copy to:
Kenneth A. Schlesinger, Esq.
Spencer Feldman, Esq.
Olshan Frome Wolosky LLP
1325 Avenue of the Americas
New York, New York 10019
(212) 451-2300
Indicate
      by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
      company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer,"
      "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated filer
☒
Smaller reporting company
☒
Emerging growth company
☐
If
      an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
      complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities
      Act.
☐
EXPLANATORY
      NOTE
Titan
      Pharmaceuticals, Inc. (the "
Company
" or the "
Registrant
") is filing this registration statement
      on Form S-8 (this "
Registration Statement
") to register an additional 2,492,424 shares (the "
Additional
      Shares
") of its common stock, par value $0.001 per share ("
Common Stock
"), issuable pursuant to the
      terms and in the manner set forth in the Company's Amended and Restated 2015 Omnibus Equity Incentive Plan, (the "
2015
      Plan
").
The
      stockholders of the Company originally approved the 2015 Plan on August 24, 2015 with 7,500,000 shares of Common Stock authorized
      for issuance under the 2015 Plan. On September 29, 2015, the Company effected a 1-for-5.5 reverse stock split, following which
      the number of shares of Common Stock authorized for issuance under the 2015 Plan was reduced from 7,500,000 to 1,363,637. In November 2015,
      the Company filed a registration statement on Form S-8 (the "
2015 Form S-8
") to register the 1,363,637 shares
      authorized under the 2015 Plan.
On
      August 2, 2016, the stockholders of the Company approved an amendment to the 2015 Plan to increase the number of shares of
      Common Stock authorized for issuance under the 2015 Plan from 1,363,637 to 2,500,000. On August 7, 2018, the stockholders
      of the Company approved an amendment to the 2015 Plan to increase the number of shares of Common Stock authorized for issuance
      under the 2015 Plan from 2,500,000 to 3,500,000. On January 23, 2019, the stockholders of the Company approved an amendment
      to the 2015 Plan to increase the number of shares of Common Stock authorized for issuance under the 2015 Plan from 3,500,000 to
      10,000,000. Also on January 23, 2019, the Company effected a 1-for-6 reverse stock split, following which the number of shares
      of Common Stock authorized for issuance under the 2015 Plan was reduced to from 10,000,000 to 1,666,667.
On
      November 30, 2020, the Company effected a 1-for-30 reverse stock split, following which the number of shares of Common Stock
      authorized for issuance under the 2015 Plan was reduced from 1,666,667 to 55,556. On January 8, 2021, the stockholders of
      the Company approved an amendment to the 2015 Plan to, among other things, increase the number of shares of Common Stock authorized
      for issuance under the 2015 Plan from 55,556 to 1,000,000.
As
      a result of the aforementioned amendments to the 2015 Plan and reverse stock splits, as of June 28 2023, there were a total of
      1,000,000 shares of Common Stock authorized under the 2015 Plan, of which only 7,576 shares were registered under the 2015 Form S-8,
      and 992,424 shares were not. On June 29, 2023, the stockholders of the Company approved an amendment to the 2015 Plan to
      increase the number of shares of Common Stock authorized for issuance under the 2015 Plan from 1,000,000 to 2,500,000. As a result,
      this Registration Statement is registering an additional 2,492,424 shares of Common Stock issuable pursuant to the 2015 Plan. The
      2,492,424 shares of Common Stock being registered on this Registration Statement includes 1,464,541 shares held by certain
      securityholders identified in the section of the Reoffer Prospectus (as defined below) entitled "Selling
      Securityholders." Such shares have been previously issued pursuant to the Company's Amended and Restated 2015 Omnibus
      Equity Incentive Plan or may be acquired in connection with stock options granted to the Selling Securityholders.
This
      Registration Statement also includes a prospectus (the "
Reoffer Prospectus
") prepared in accordance with General
      Instruction C of Form S-8 and in accordance with the requirements of Part I of Form S-3. This Reoffer Prospectus may be used for
      the reoffer and resale of shares of Common Stock on a continuous or delayed basis that may be deemed to be "restricted securities"
      and/or "control securities" within the meaning of the Securities Act of 1933, as amended (the "
Securities
      Act
"), and the rules and regulations promulgated thereunder, that have previously been issued to certain of our executive
      officers, employees, consultants and directors identified in the Reoffer Prospectus. The number of shares of Common Stock included
      in the Reoffer Prospectus represents shares of Common Stock (i) issued to the selling stockholders pursuant to equity awards or
      (ii) issuable pursuant to stock options granted to the selling stockholders, and does not necessarily represent a present intention
      to sell any or all such shares of Common Stock.
PART
      I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
Item
            1.
Plan
            Information.
The
      Company will provide each recipient of a grant under the 2015 Plan (the "
Recipients
") with documents that contain
      information related to the 2015 Plan, and other information including, but not limited to, the disclosure required by Item 1 of
      Form S-8, which information is not required to be and is not being filed as a part of this Registration Statement on Form S-8 (the
      "
Registration Statement
") or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities
      Act. The foregoing information and the documents incorporated by reference in response to Item 3 of Part II of this Registration
      Statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act. A Section 10(a)
      prospectus will be given to each Recipient who receives shares of Common Stock covered by this Registration Statement, in accordance
      with Rule 428(b)(1) under the Securities Act.
Item
            2.
Registrant
            Information and Employee Plan Annual Information.
We
      will provide to each Recipient a written statement advising of the availability of documents incorporated by reference in Item
      3 of Part II of this Registration Statement (which documents are incorporated by reference in this Section 10(a) prospectus)
      and of documents required to be delivered pursuant to Rule 428(b) under the Securities Act without charge and upon written
      or oral request by contacting:
Kate
Beebe DeVarney, Ph.D., President and Chief Operating Officer
Titan
Pharmaceuticals, Inc.
400
Oyster Point Blvd., Suite 505
South
      San Francisco, California 94080
REOFFER
      PROSPECTUS
1,464,541
Shares
Common
Stock Issued Under the 2015 Plan and
Certain
      Awards Granted Outside of the 2015 Plan
This
      Reoffer Prospectus relates to the public resale, from time to time, of an aggregate of 1,464,541 shares (the "
Shares
")
      of our common stock, $0.001 par value per share (the "
Common Stock
") by certain securityholders identified herein
      in the section entitled "Selling Securityholders." Such shares have been previously issued pursuant to the Company's
      Amended and Restated 2015 Omnibus Equity Incentive Plan or may be acquired in connection with stock options granted to the Selling
      Securityholders. You should read this prospectus carefully before you invest in our Common Stock.
Such
      resales shall take place on The Nasdaq Capital Market, or such other stock market or exchange on which our Common Stock may be
      listed or quoted, in negotiated transactions or otherwise, at market prices prevailing at the time of the sale or at prices otherwise
      negotiated (see "Plan of Distribution" starting on page 6 of this prospectus). We will receive no part of the proceeds
      from sales made under this Reoffer Prospectus. The Selling Securityholders will bear all sales commissions and similar expenses.
      Any other expenses incurred by us in connection with the registration and offering and not borne by the Selling Securityholders
      will be borne by us.
This
      Reoffer Prospectus has been prepared for the purposes of registering our shares of Common Stock under the Securities Act to allow
      for future sales by Selling Securityholders on a continuous or delayed basis to the public without restriction. We have not entered
      into any underwriting arrangements in connection with the sale of the shares covered by this Reoffer Prospectus. The Selling Securityholders
      identified in this Reoffer Prospectus, or their pledgees, donees, transferees or other successors-in-interest, may offer the shares
      covered by this Reoffer Prospectus from time to time through public or private transactions at prevailing market prices, at prices
      related to prevailing market prices or at privately negotiated prices.
Investing
      in our Common Stock involves risks. See "Risk Factors" beginning on page 3 of this Reoffer Prospectus. These are speculative
      securities.
Our
      Common Stock trades on The Nasdaq Capital Market under the symbol "TTNP." On October 23, 2023, the last reported
      sale price of our Common Stock on The Nasdaq Capital Market was $0.34 per share.
NEITHER
      THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED
      IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
The
      date of this prospectus is October 24, 2023
TABLE
      OF CONTENTS
Cautionary Statement Regarding Forward-Looking Statements
1
Prospectus Summary
2
Risk Factors
5
Use of Proceeds
6
Selling Securityholders
7
Plan of Distribution
9
Legal Matters
11
Experts
11
Disclosure of Commission Position on Indemnification For Securities Act Liabilities
11
Where You Can Find Additional Information
11
Incorporation of Certain Documents by Reference
12
i
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This prospectus contains "forward-looking statements" that involve substantial risks
         and uncertainties. All statements other than statements of historical facts contained
         in this prospectus, including statements regarding our future results of operations
         and financial position, strategy and plans, and our expectations for future operations,
         are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Exchange Act. We have attempted to identify forward-looking statements by
         terminology including "anticipates," "believes," "can," "continue," "could," "estimates,"
         "expects," "intends," "may," "plans," "potential," "predicts," "should," or "will"
         or the negative of these terms or other comparable terminology. Although we do not
         make forward looking statements unless we believe we have a reasonable basis for doing
         so, we cannot guarantee their accuracy. Forward-looking statements included or incorporated
         by reference in this prospectus or our other filings with the SEC include, but are
         not necessarily limited to, those relating to uncertainties relating to:
●
our ability to raise capital when needed;
●
difficulties or delays in the product development process, including the results of
               preclinical studies or clinical trials;
●
financing and strategic agreements and relationships;
●
difficulties or delays in the regulatory approval process;
●
adverse side effects or inadequate therapeutic efficacy of our drug candidates that
               could slow or prevent product development or commercialization;
●
dependence on third-party suppliers;
●
uncertainties relating to manufacturing, sales, marketing and distribution of our
               drug candidates that may be successfully developed and approved for commercialization;
●
the uncertainty of protection for our patents and other intellectual property or trade
               secrets; and
●
competition.
These statements are only predictions and involve known and unknown risks, uncertainties
         and other factors, including the risks outlined under "Risk Factors" or elsewhere
         in this prospectus, which may cause our or our industry's actual results, levels of activity, performance or achievements expressed or implied
         by these forward-looking statements.
Forward-looking statements should not be read as a guarantee of future performance
         or results, and will not necessarily be accurate indications of the times at, or by
         which, that performance or those results will be achieved. Forward-looking statements
         are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events, and are subject
         to risks and uncertainties that could cause actual performance or results to differ
         materially from what is expressed in or suggested by the forward-looking statements.
Forward-looking statements speak only as of the date they are made. You should not
         put undue reliance on any forward-looking statements. We assume no obligation to update
         forward-looking statements to reflect actual results, changes in assumptions or changes
         in other factors affecting forward-looking information, except to the extent required
         by U.S. federal securities laws. If we do update one or more forward-looking statements,
         no inference should be drawn that we will make additional updates with respect to
         those or other forward-looking statements. We caution you not to give undue weight
         to such projections, assumptions and estimate.
1
PROSPECTUS SUMMARY
The SEC allows us to "incorporate by reference" certain information that we file with the SEC, which means that we can disclose important
         information to you by referring you to those documents. The information incorporated
         by reference is considered to be part of this prospectus, and information that we
         file later with the SEC will update automatically, supplement and/or supersede the
         information disclosed in this prospectus. Any statement contained in a document incorporated
         or deemed to be incorporated by reference in this prospectus shall be deemed to be
         modified or superseded for purposes of this prospectus to the extent that a statement
         contained in this prospectus or in any other document that also is or is deemed to
         be incorporated by reference in this prospectus modifies or supersedes such statement.
         Any such statement so modified or superseded shall not be deemed, except as so modified
         or superseded, to constitute a part of this prospectus. You should read the following
         summary together with the more detailed information regarding our company, our Common
         Stock and our financial statements and notes to those statements appearing elsewhere
         in this prospectus or incorporated herein by reference.
Our Company
Overview of our Business
We are a pharmaceutical company developing therapeutics utilizing a proprietary long-term drug delivery platform, ProNeura
®
, for the treatment of select chronic diseases for which steady state delivery of
         a drug has the potential to provide an efficacy and/or safety benefit. ProNeura consists
         of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and
         a drug substance. The resulting product is a solid matrix that is designed to be administered
         subdermally in a brief, outpatient procedure and is removed in a similar manner at
         the end of the treatment period.
Our first product based on the ProNeura technology is Probuphine® (buprenorphine implant), which is approved in
         the United States, Canada and the European Union, or EU, for the maintenance treatment
         of opioid use disorder in clinically stable patients taking 8 mg or less a day of
         oral buprenorphine. While Probuphine continues to be commercialized in Canada and
         the EU (as Sixmo™) by other companies that have either licensed or acquired the rights
         from us, we discontinued commercialization of the product in the United States during
         the fourth quarter of 2020 to allow us to focus our limited resources on other product
         development programs.
In December 2021, we announced our intention to work with our financial advisor to explore strategic
         alternatives to enhance stockholder value, potentially including an acquisition, merger,
         reverse merger, sale of assets, licensing or other business combination transaction.
         In June 2022, we implemented a plan to reduce expenses and conserve capital that included a
         company-wide reduction in salaries and a scale back of certain operating expenses
         to enable us to maintain sufficient resources as we pursued potential strategic alternatives.
         In July 2022, David E. Lazar and Activist Investing LLC acquired an approximately 25% ownership
         interest in our company, filed a proxy statement and nominated six additional directors,
         each of whom was elected to our board of directors at a special meeting of stockholders
         held on August 15, 2022 (the "Special Meeting"). The exploration and evaluation of possible strategic
         alternatives by the Board has continued following the Special Meeting. To date, we
         have no commitments with respect to any such strategic alternatives. Following the
         election of new directors at the Special Meeting, Dr. Marc Rubin was replaced as our
         Executive Chairman and Mr. Lazar assumed the position of Chief Executive Officer. In connection with Dr. Rubin's cessation of employment as Executive Chairman, we agreed to make aggregate severance
         payments to him of approximately $400,000, of which approximately $247,000 had been
         paid as of March 31, 2023. In December 2022, we implemented additional cost reduction measures including a reduction in our
         workforce. On June 21, 2023, Mr. Lazar entered into and completed a Share Transfer Agreement with Choong Choon Hau,
         pursuant to which Mr. Lazar sold all of his beneficial ownership interests in our company (excluding equity
         based compensation) to Mr. Choong.
2
On July 26, 2023, the Company entered into an asset purchase agreement (the "Asset Purchase Agreement") with Fedson,
         Inc., a Delaware corporation ("Fedson") for the sale of certain ProNeura assets including
         Titan's portfolio of drug addiction products, in addition to other early development programs
         based on the ProNeura drug delivery technology (the "ProNeura Assets"). The Company's addiction portfolio consists of the Probuphine and Nalmefene implant programs. The
         ProNeura Assets constitute only a portion of Titan's assets. On August 25, 2023, the Company entered into an Amendment and Extension Agreement with respect to the Asset Purchase Agreement, pursuant to which Fedson agreed to purchase the ProNeura Assets for a purchase price of $2,000,000, consisting of (i) $500,000 in readily available funds, to be paid in full on the
         Closing Date (the "Closing Cash"), (ii) $500,000 in the form of a promissory note
         due and payable on October 1, 2023 (the "Cash Note") and (iii) $1,000,000 in the form of a promissory note due
         and payable on January 1, 2024 (the "Escrow Note", and together with the Closing Cash and the Cash Note, the
         "Closing Consideration"). On the Closing Date, Fedson delivered to the Company a written guaranty by a principal of Fedson of all of Fedson's obligations under both the Cash Note and Escrow Note. In consideration for an extension of the Closing Date to September 1, 2023, Fedson paid the Company an advance of $250,000 against the Closing Consideration. On September 29, 2023, and in accordance with the terms of the Cash Note, Fedson paid the Company
         $5,000 to extend the payment date of the Cash Note to November 1, 2023.
In August 2023, the Company received $500,000 in funding in exchange for the issuance of a convertible promissory
         note for that principal amount to Choong Choon Hau (the "Hau Promissory Note"). Pursuant
         to the Hau Promissory Note, the principal amount will accrue interest at a rate of
         10% per annum and will be payable monthly. All principal and accrued interest shall
         be due and payable on January 1, 2024, unless extended as provided. All or part of the Hau Promissory Note can be
         converted into our Common Stock at a conversion price of $0.5712 per share from time to time following the issuance date and ending on the maturity
         date.
On September 13, 2023, the Company entered into a Securities Purchase Agreement (the "Purchase Agreement")
         with The Sire Group Ltd. ("Sire Group" or the "Investor"), pursuant to which the Company
         agreed to issue 950,000 shares of Series AA Convertible Preferred Stock, par value
         $0.001 per share to Sire Group at a price of $10.00 per share, for an aggregate purchase price of $9,500,000. The purchase price consisted of (i) $5 million in cash at closing and (ii) $4.5 million in the form of a promissory
         note from Sire Group, personally guaranteed by a principal of Sire Group, due and
         payable on September 23, 2023, subject to two 10-day extensions which include additional payments of $50,000
         for each extension. Sire Group remitted the $4.5 million principal under the promissory note on September 26, 2023.
3
The Offering
Outstanding Common Stock:
15,016,295 shares of our Common Stock are outstanding as of October 24, 2023.
Common Stock Offered:
Up to 1,464,541 shares of Common Stock for sale by the Selling Securityholders (which include our executive officers and directors) for their own account pursuant
               to the 2015 Plan.
Selling Securityholders:
The Selling Securityholders are set forth in the section entitled "Selling Securityholders" of this Reoffer Prospectus on page 4. The amount of securities to be offered or resold by means of the Reoffer Prospectus by the designated Selling Securityholders may not exceed, during any three-month period, the amount specified in Rule 144(e).
Use of proceeds:
We will not receive any proceeds from the sale of our Common Stock by the Selling Securityholders. We would, however, receive proceeds upon the exercise of the stock options by those
               who receive options under the 2015 Plan and exercise such options for cash. Any cash proceeds will be used by us for general
               corporate purposes.
Risk Factors:
The securities offered hereby involve a high degree of risk. See "Risk Factors."
Nasdaq Capital Market trading symbol
"TTNP"
4
RISK FACTORS
An investment in our securities involves a high degree of risk. You should carefully consider the risks, uncertainties and assumptions discussed in Item
         1A., "Risk Factors" of our annual report on Form 10-K for the fiscal year ended December 31, 2022, in Item 1A., "Risk Factors" of our quarterly reports on Form 10-Q for the
         quarters ended March 31, 2023 and June 30, 2023, and in other documents that we subsequently file with the SEC that update,
         supplement or supersede such information, which documents are incorporated by reference
         into this Reoffer Prospectus. Additional risks not presently known to us or which we consider immaterial based
         on information currently available to us may also materially adversely affect us.
         If any of the events anticipated by the risks described occur, our results of operations
         and financial condition could be adversely affected, which could result in a decline
         in the market price of our common stock, causing you to lose all or part of your investment.
5
USE OF PROCEEDS
The shares which may be sold under this Reoffer Prospectus will be sold for the respective accounts of each of the Selling Securityholders listed
         herein (which includes our executive officers and directors). Accordingly, we will
         not realize any proceeds from the sale of the shares of our Common Stock. We will
         receive proceeds from the exercise of the options; however, no assurance can be given
         as to when or if any or all of the options will be exercised. If any options are exercised,
         the proceeds derived therefrom will be used for working capital and general corporate
         purposes. All expenses of the registration of the shares will be paid by us. See "Selling
         Securityholders" and "Plan of Distribution."
6
SELLING SECURITYHOLDERS
We are registering for resale the shares covered by this prospectus to permit the
         Selling Securityholders identified below and their pledgees, donees, transferees and
         other successors-in-interest that receive their securities from a Selling Securityholder
         as a gift, partnership distribution or other non-sale related transfer after the date
         of this prospectus to resell the shares when and as they deem appropriate. The Selling
         Securityholders acquired, or may acquire, these shares from us pursuant to the 2015 Plan. The shares may not be sold or otherwise transferred by the Selling Securityholders
         unless and until the applicable awards vest and are exercised, as applicable, in accordance
         with the terms and conditions of the 2015 Plan.
The following table sets forth:
●
the name of each Selling Securityholder;
●
the position(s), office or other material relationship with our company and its predecessors
               or affiliates, over the last three years of each Selling Securityholder;
●
the number and percentage of shares of our Common Stock that each Selling Securityholder
               beneficially owned as of October 24, 2023 prior to the offering for resale of the shares under this prospectus;
●
the number of shares of our Common Stock that may be offered for resale for the account
               of each Selling Securityholder under this prospectus; and
●
the number and percentage of shares of our Common Stock to be beneficially owned by
               each Selling Securityholder after the offering of the resale shares (assuming all
               of the offered resale shares are sold by such Selling Securityholder).
Information with respect to beneficial ownership is based upon information obtained
         from the Selling Securityholders. Because the Selling Securityholders may offer all
         or part of the shares of Common Stock, which they own pursuant to the offering contemplated
         by this Reoffer Prospectus, and because its offering is not being underwritten on a firm commitment basis, no
         estimate can be given as to the amount of shares that will be held upon termination
         of this offering.
The number of shares in the column "Number of Shares Being Offered" represents the shares of our Common Stock that each Selling Securityholder may offer
         under this prospectus ("Shares"). We do not know how long the Selling Securityholders
         will hold the Shares before selling them or how many Shares they will sell. The shares of our Common Stock offered by this prospectus may be offered
         from time to time by the Selling Securityholders listed below. We cannot assure you
         that any of the Selling Securityholders will offer for sale or sell any or all of
         the shares of Common Stock offered by them by this prospectus.
Number
of
Shares Beneficially
Owned Prior
to
Offering (1)
Number
of
Shares Being
Number of
Shares Beneficially
Owned After
Offering (2)
Securityholders
Number
Percent (%)
Offered
Number
Percent (%)
David E. Lazar (3)
100,000
*
100,000
-
-%
Kate Beebe DeVarney, Ph.D. (4)
356,533
2.3
356,533
-
-%
Avraham Ben-Tzvi (5)
175,000
1.2
175,000
-
-%
Eric Greenberg (6)
175,000
1.2
175,000
-
-%
Matthew C. McMurdo (7)
175,000
1.2
175,000
-
-%
David Natan (8)
175,000
1.2
175,000
-
-%
Brian Crowley (9)
133,008
*
133,008
-
-%
Peter L. Chasey (10)
175,000
1.2
175,000
-
-%
Total:
1,464,541
*
Indicates beneficial ownership of less than 1% of the outstanding
Common Stock
7
(1)
The number and percentage of shares beneficially owned is determined in accordance
               with Rule 13d-3 of the Securities Exchange Act of 1934, as amended, and the information is not
               necessarily indicative of beneficial ownership for any other purpose. Under such rule,
               beneficial ownership includes any shares as to which the Selling Securityholder has
               sole or shared voting power or investment power and also any shares which the Selling
               Securityholder has the right to acquire within 60 days. Applicable percentage ownership
               is based on 15,016,295 shares of Common Stock outstanding as of October 24, 2023.
(2)
Assumes that all shares of Common Stock to be offered, as set forth above, are sold
               pursuant to this offering and that no other shares of Common Stock are acquired or
               disposed of by the Selling Securityholders prior to the termination of this offering.
               Because the Selling Securityholders may sell all, some or none of their shares of
               Common Stock or may acquire or dispose of other shares of Common Stock, no reliable
               estimate can be made of the aggregate number of shares of Common Stock that will be
               sold pursuant to this offering or the number or percentage of shares of Common Stock
               that each Selling Securityholder will own upon completion of this offering.
(3)
Mr. Lazar is our Chief Executive
            Officer and our former Chairman of the Board.
(4)
Dr. Beebe DeVarney is our President and Chief Operating Officer and a member of the Board. The shares of Common Stock beneficially owned include 306,553 shares of common stock subject to options exercisable within 60 days of October 24, 2023.
(5)
Mr. Ben-Tzvi is a member of the Board. The shares of Common Stock beneficially owned include 125,000 shares of common stock subject to options exercisable within 60 days of October 24, 2023.
(6)
Mr. Greenberg is a member of the Board. The shares of Common Stock beneficially owned include 125,000 shares of common stock subject to options exercisable within 60 days of October 24, 2023.
(7)
Mr. McMurdo is a member of the Board. The shares of Common Stock beneficially owned include 125,000 shares of common stock subject to options exercisable within 60 days of October 24, 2023.
(8)
Mr. Natan is a member of the Board. The shares of Common Stock beneficially owned include 125,000 shares of common stock subject to options exercisable within 60 days of October 24, 2023.
(9)
Mr. Crowley is our Sr. Vice President, Finance. The shares of Common Stock beneficially
               owned include 83,008 shares of common stock subject to options exercisable within 60 days of October 24, 2023.
(10)
Mr. Chasey is a former member of the Board. The shares of Common Stock beneficially owned include 125,000 shares of common stock subject to options exercisable within 60 days of October 24, 2023.
8
PLAN OF DISTRIBUTION
We are registering the Shares covered by this prospectus to permit the Selling Stockholders
         to conduct public secondary trading of these Shares from time to time after the date
         of this prospectus. We will not receive any of the proceeds of the sale of the Shares
         offered by this prospectus. The aggregate proceeds to the Selling Stockholders from
         the sale of the Shares will be the purchase price of the Shares less any discounts
         and commissions. We will not pay any brokers' or underwriters' discounts and commissions in connection with the registration and sale of the Shares
         covered by this prospectus. The Selling Stockholders reserve the right to accept and,
         together with their respective agents, to reject, any proposed purchases of Shares
         to be made directly or through agents.
The Shares offered by this prospectus may be sold from time to time to purchasers:
●
directly by the Selling Stockholders, or
●
through underwriters, broker-dealers or agents, who may receive compensation in the
               form of discounts, commissions or agent's commissions from the Selling Stockholders or the purchasers of the Shares.
Any underwriters, broker-dealers or agents who participate in the sale or distribution
         of the Shares may be deemed to be "underwriters" within the meaning of the Securities
         Act. As a result, any discounts, commissions or concessions received by any such broker-dealer
         or agents who are deemed to be underwriters will be deemed to be underwriting discounts
         and commissions under the Securities Act. Underwriters are subject to the prospectus
         delivery requirements of the Securities Act and may be subject to certain statutory
         liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended
         (the "Exchange Act"). We will make copies of this prospectus available to the Selling
         Stockholders for the purpose of satisfying the prospectus delivery requirements of
         the Securities Act. To our knowledge, there are currently no plans, arrangements or
         understandings between the Selling Stockholders and any underwriter, broker-dealer
         or agent regarding the sale of the Shares by the Selling Stockholders.
The Shares may be sold in one or more transactions at:
●
fixed prices;
●
prevailing market prices at the time of sale;
●
prices related to such prevailing market prices;
●
varying prices determined at the time of sale; or
●
negotiated prices.
These sales may be effected in one or more transactions:
●
on any national securities exchange or quotation service on which the Shares may be
               listed or quoted at the time of sale, including the The Nasdaq Capital Market;
●
in the over-the-counter market;
9
●
in transactions otherwise than on such exchanges or services or in the over-the-counter
               market;
●
any other method permitted by applicable law; or
●
through any combination of the foregoing.
These transactions may include block transactions or crosses. Crosses are transactions
         in which the same broker acts as an agent on both sides of the trade.
At the time a particular offering of the Shares is made, a prospectus supplement,
         if required, will be distributed, which will set forth the name of the Selling Stockholders,
         the aggregate amount of Shares being offered and the terms of the offering, including,
         to the extent required, (1) the name or names of any underwriters, broker-dealers
         or agents, (2) any discounts, commissions and other terms constituting compensation
         from the Selling Stockholders and (3) any discounts, commissions or concessions allowed
         or reallowed to be paid to broker-dealers.
The Selling Stockholders will act independently of us in making decisions with respect
         to the timing, manner, and size of each resale or other transfer. There can be no
         assurance that the Selling Stockholders will sell any or all of the Shares under this
         prospectus. Further, we cannot assure you that the Selling Stockholders will not transfer,
         distribute, devise or gift the Shares by other means not described in this prospectus.
         In addition, any Shares covered by this prospectus that qualify for sale under Rule 144 of the Securities Act may be sold under Rule 144 rather than under this prospectus. The Shares may be sold in some states only through
         registered or licensed brokers or dealers. In addition, in some states the Shares
         may not be sold unless they have been registered or qualified for sale or an exemption
         from registration or qualification is available and complied with.
The Selling Stockholders and any other person participating in the sale of the Shares
         will be subject to the Exchange Act. The Exchange Act rules include, without limitation,
         Regulation M, which may limit the timing of purchases and sales of any of the Shares
         by the Selling Stockholders and any other person. In addition, Regulation M may restrict
         the ability of any person engaged in the distribution of the Shares to engage in market-making
         activities with respect to the particular Shares being distributed. This may affect
         the marketability of the Shares and the ability of any person or entity to engage
         in market-making activities with respect to the Shares.
The Selling Stockholders may indemnify any broker or underwriter that participates
         in transactions involving the sale of the Shares against certain liabilities, including
         liabilities arising under the Securities Act.
10
LEGAL MATTERS
The validity of the issuance of the securities offered by this prospectus will be
         passed upon for us by Olshan Frome Wolosky LLP, New York, New York.
EXPERTS
The financial statements of Titan Pharmaceuticals, Inc. included in our annual report
         on Form 10-K for the fiscal years ended December 31, 2022 and 2021 have been audited by WithumSmith+Brown, PC, independent registered public
         accountants, as set forth in their reports thereon, included therein, and incorporated
         herein by reference in this prospectus, which report includes an explanatory paragraph about the existence of substantial
         doubt concerning the Company's ability to continue as a going concern, and elsewhere in the registration statement. Such financial statements are incorporated
         herein by reference in reliance upon such reports given on the authority of said firm
         as experts in accounting and auditing.
DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION
FOR SECURITIES ACT LIABILITIES
Insofar as indemnification for liabilities arising under the Securities Act may be
         permitted to directors, officers or persons controlling the registrant, the registrant
         has been informed that in the opinion of the Commission such indemnification is against
         public policy as expressed in the Securities Act and is therefore unenforceable.
WHERE YOU CAN FIND MORE INFORMATION
We file annual reports, quarterly and
      current reports, proxy statements and other information with the SEC. The SEC maintains an Internet website that contains reports,
      proxy and information statements, and other information regarding issuers that file electronically with the SEC at
www.sec.gov
.
We maintain an Internet website at www.titanpharm.com. All of our reports filed with
         the SEC (including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current
         Reports on Form 8-K and proxy statements) are accessible through the Investor Relations
         section of our website, free of charge, as soon as reasonably practicable after electronic
         filing. The reference to our website in this prospectus is an inactive textual reference
         only and is not a hyperlink. The contents of our website are not part of this prospectus,
         and you should not consider the contents of our website in making an investment decision
         with respect to our securities.
11
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference
The following documents previously filed with the Commission by the Company are incorporated by reference herein:
(1)
The Annual Report on
Form 10-K
for the year ended December 31, 2022, filed with the Commission on March 31, 2023;
(2)
The Quarterly Reports on Form 10-Q (i) for the fiscal quarter ended March 31, 2023, filed with the Commission on
May 15, 2023
and (ii) for the fiscal quarter ended June 30, 2023, filed with the Commission on
August 14, 2023
;
(3)
The Current Reports on Form 8-K (other than information furnished rather than filed) filed with the Commission on
January 6, 2023
,
February 9, 2023
,
March 3, 2023
,
March 22, 2023
,
April 11, 2023
,
June 6, 2023
,
June 29, 2023
,
July 7, 2023
,
July 28, 2023
,
August 30, 2023
,
September 8, 2023
,
September 18, 2023
, as amended, and
October 16, 2023
; and
(4)
The Definitive Proxy Statement on
Schedule 14A
, filed with the SEC on May 19, 2023; and
(5)
The description of common stock contained in Forms 8 and 8-A previously filed with the Commission and any amendments or reports filed for the purpose of updating such description.
All documents filed by the Company pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934 (other than documents
         or information deemed to have been "furnished" and not "filed") after the date hereof
         and before the filing of a post-effective amendment that indicates that all securities
         offered hereby have been sold or that deregisters all securities then remaining unsold
         shall be deemed to be incorporated by reference herein and to be part hereof from
         the date of filing those documents. Any statement contained in any document incorporated
         or deemed to be incorporated by reference herein shall be deemed to be modified or
         superseded for purposes of this registration statement to the extent that a statement
         contained herein or in any subsequently filed document which is or is deemed to be
         incorporated by reference herein modifies or supersedes the statement. Any statement
         so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.
Item 4. Description of Securities.
Not applicable.
Item 5. Interests of Named Experts and Counsel.
None.
Item 6. Indemnification of Directors and Officers
.
Amended and Restated Bylaws
Pursuant to our bylaws, our directors and officers will be indemnified to the fullest
         extent allowed under the laws of the State of Delaware for their actions in their
         capacity as our directors and officers.
12
We must indemnify any person made a party to any threatened, pending, or completed
         action, suit, or proceeding, whether civil, criminal, administrative, or investigative
         ("Proceeding") by reason of the fact that he is or was a director, against judgments,
         penalties, fines, settlements and reasonable expenses (including attorney's fees) ("Expenses") actually and reasonably incurred by him in connection with such
         Proceeding if: (a) he conducted himself in good faith, and: (i) in the case of conduct
         in his own official capacity with us, he reasonably believed his conduct to be in
         our best interests, or (ii) in all other cases, he reasonably believes his conduct
         to be at least not opposed to our best interests; and (b) in the case of any criminal
         Proceeding, he had no reasonable cause to believe his conduct was unlawful. We must
         indemnify any person made a party to any Proceeding by or in the right of us, by reason
         of the fact that he is or was a director, against reasonable expenses actually incurred
         by him in connection with such proceeding if he conducted himself in good faith, and:
         (a) in the case of conduct in his official capacity with us, he reasonably believed
         his conduct to be in our best interests; or (b) in all other cases, he reasonably
         believed his conduct to be at least not opposed to our best interests; provided that
         no such indemnification may be made in respect of any proceeding in which such person
         shall have been adjudged to be liable to us. No indemnification will be made by unless
         authorized in the specific case after a determination that indemnification of the
         director is permissible in the circumstances because he has met the applicable standard
         of conduct. Reasonable expenses incurred by a director who is party to a proceeding
         may be paid or reimbursed by us in advance of the final disposition of such Proceeding
         in certain cases.
We have the power to purchase and maintain insurance on behalf of any person who is
         or was our director, officer, employee, or agent or is or was serving at our request
         as an officer, employee or agent of another corporation, partnership, joint venture,
         trust, other enterprise, or employee benefit plan against any liability asserted against
         him and incurred by him in any such capacity or arising out of his status as such,
         whether or not we would have the power to indemnify him against such liability under
         the provisions of the amended and restated bylaws.
Delaware Law
Section 145 of the Delaware General Corporation Law provides that a Delaware corporation may
         indemnify any persons who are, or are threatened to be made, parties to any threatened,
         pending or completed action, suit or proceeding, whether civil, criminal, administrative
         or investigative (other than an action by or in the right of such corporation), by
         reason of the fact that such person was an officer, director, employee or agent of
         such corporation, or is or was serving at the request of such person as an officer,
         director, employee or agent of another corporation or enterprise. The indemnity may
         include expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred
         by such person in connection with such action, suit or proceeding, provided that such
         person acted in good faith and in a manner he or she reasonably believed to be in
         or not opposed to the corporation's best interests and, with respect to any criminal action or proceeding, had no reasonable
         cause to believe that his or her conduct was illegal. A Delaware corporation may indemnify
         any persons who are, or are threatened to be made, a party to any threatened, pending
         or completed action or suit by or in the right of the corporation by reason of the
         fact that such person was a director, officer, employee or agent of such corporation,
         or is or was serving at the request of such corporation as a director, officer, employee
         or agent of another corporation or enterprise. The indemnity may include expenses
         (including attorneys' fees) actually and reasonably incurred by such person in connection with the defense
         or settlement of such action or suit provided such person acted in good faith and
         in a manner he or she reasonably believed to be in or not opposed to the corporation's best interests except that no indemnification is permitted without judicial approval
         if the officer or director is adjudged to be liable to the corporation. Where an officer
         or director is successful on the merits or otherwise in the defense of any action
         referred to above, the corporation must indemnify him or her against the expenses
         which such officer or director has actually and reasonably incurred. Our amended and
         restated certificate of incorporation and amended and restated bylaws provide for
         the indemnification of our directors and officers to the fullest extent permitted
         under the Delaware General Corporation Law.
13
Section 102(b)(7) of the Delaware General Corporation Law permits a corporation to provide
         in its certificate of incorporation that a director of the corporation shall not be
         personally liable to the corporation or its stockholders for monetary damages for
         breach of fiduciary duties as a director, except for liability for any:
●
transaction from which the director derives an improper personal benefit;
●
act or omission not in good faith or that involves intentional misconduct or a knowing
               violation of law;
●
unlawful payment of dividends or redemption of shares; or
●
breach of a director's duty of loyalty to the corporation or its stockholders.
Our amended and restated certificate of incorporation and amended and restated bylaws
         include such a provision. Expenses incurred by any officer or director in defending
         any such action, suit or proceeding in advance of its final disposition shall be paid
         by us upon delivery to us of an undertaking, by or on behalf of such director or officer,
         to repay all amounts so advanced if it shall ultimately be determined that such director
         or officer is not entitled to be indemnified by us.
Section 174 of the Delaware General Corporation Law provides, among other things, that a director
         who willfully or negligently approves of an unlawful payment of dividends or an unlawful
         stock purchase or redemption may be held liable for such actions. A director who was
         either absent when the unlawful actions were approved, or dissented at the time, may
         avoid liability by causing his or her dissent to such actions to be entered in the
         books containing minutes of the meetings of the board of directors at the time such
         action occurred or immediately after such absent director receives notice of the unlawful
         acts.
Indemnification Agreements
As permitted by the Delaware General Corporation Law, we have entered, and intend
         to continue to enter, into separate indemnification agreements with each of our directors
         and executive officers, that require us to indemnify such persons against any and
         all expenses (including attorneys' fees), witness fees, damages, judgments, fines, settlements and other amounts incurred
         (including expenses of a derivative action) in connection with any action, suit or
         proceeding, whether actual or threatened, to which any such person may be made a party
         by reason of the fact that such person is or was a director, an officer or an employee
         of us or any of our affiliated enterprises, provided that such person acted in good
         faith and in a manner such person reasonably believed to be in or not opposed to our
         best interests and, with respect to any criminal proceeding,
Item 7. Exemption from Registration Claimed
.
Not applicable.
14
Item 8. Exhibits.
Exhibit
    No.
Description
    of Exhibit
3.1.1
Amended and Restated Certificate of Incorporation of the Registrant, as amended (incorporated by reference to Exhibit 3.1 to the Company's Registration Statement on Form 10 filed on January 14, 2010)
.
3.1.2
Certificate of Amendment to the Restated Certificate of Incorporation dated September 24, 2015 (incorporated by reference to Exhibit 3.1 to the Company's
Current Report on Form 8-K filed on September 28, 2015
).
3.1.3
Certificate of Amendment to the Restated Certificate of Incorporation dated January 23, 2019 (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K dated January 25, 2019.
3.1.4
Certificate of Amendment to the Restated Certificate of Incorporation dated November 30, 2020 (incorporated by reference to Exhibit 3.1 to the Company's
Current Report on Form 8-K dated December 1, 2020
).
3.2
By-laws of the Registrant (incorporated by reference to Exhibit 3.3 to the Company's
Registration Statement on Form S-3 (File No. 333-221126))
.
3.3
Amendment to the By-laws of the Registrant dated December 29, 2021 (incorporated by reference to Exhibit 3.1 to the Company's
Current Report on Form 8-K dated December 29, 2021
).
3.4
Amendment to the By-laws of the Registrant dated July 5, 2022 (incorporated by reference to Exhibit 3.1 to the Company's
Current Report on Form 8-K dated July 5, 2022)
.
5.1*
Opinion of Olshan Frome Wolosky LLP, counsel to the Company.
10.14
Form of Stock Option Agreement (incorporated by reference to Exhibit 10.1 to the Company's
Current Report on Form 8-K dated September 21, 2022
).
10.15
Fifth Amended and Restated 2015 Omnibus Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company's
Quarterly Report on Form 10-Q for the period ended September 30, 2022
).
23.1*
Consent of WithumSmith+Brown, P.C., independent registered public accounting firm.
23.2*
Consent of Olshan Frome Wolosky LLP (included in Exhibit 5.1).
24.1*
Powers of Attorney (included on the signature pages to this Registration Statement).
107*
Filing Fee Table.
*
Filed herewith.
15
Item 9. Undertakings
(a) The undersigned registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a post-effective
         amendment to this registration statement:
(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
(ii) To reflect in the prospectus any facts or events arising after the effective
         date of the registration statement (or the most recent post-effective amendment thereof)
         which, individually or in the aggregate, represent a fundamental change in the information
         set forth in the registration statement. Notwithstanding the foregoing, any increase
         or decrease in volume of securities offered (if the total dollar value of securities
         offered would not exceed that which was registered) and any deviation from the low
         or high end of the estimated maximum offering range may be reflected in the form of
         prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than
         a 20 percent change in the maximum aggregate offering price set forth in the "Calculation
         of Registration Fee" table in the effective registration statement; and
(iii) To include any material information with respect to the plan of distribution
         not previously disclosed in the registration statement or any material change to such
         information in this registration statement.
Provided, however
, that the undertakings set forth in paragraphs (a)(1)(i) and (a)(1)(ii) above do
         not apply if the information required to be included in a post-effective amendment
         by those paragraphs is contained in reports filed with or furnished to the Commission
         by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in
         the registration statement.
(2) That, for the purpose of determining any liability under the Securities Act of
         1933, each such post-effective amendment shall deemed to be a new registration statement
         relating to the securities offered therein, and the offering of such securities at
         that time shall be deemed to be the initial bona fide offering thereof.
(3) To remove from registration by means of a post-effective amendment any of the
         securities being registered which remain unsold at the termination of the offering.
(b) The undersigned registrant hereby undertakes
      that for the purpose of determining any liability under the Securities Act of 1933, each filing of the registrant's annual
      report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an
      employee benefit plan's annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is
      incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the
      securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
      thereof.
(c) Insofar as indemnification for liabilities
      arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant
      to the foregoing provisions or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification
      is against public policy as expressed in the Securities Act of 1933 and is therefore unenforceable. In the event that a claim for
      indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director,
      officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such
      director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the
      opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
      question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933, and will be
      governed by the final adjudication of such issue.
16
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of
         the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Dubai, United Arab Emirates on the 24
th
day of October, 2023.
TITAN PHARMACEUTICALS, INC.
By:
/s/ David E. Lazar
Name:
David E. Lazar
Title:
Chief Executive Officer
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, each director and officer whose signature appears
         below constitutes and appoints each of David E. Lazar and Katherine Beebe DeVarney, Ph.D. his true and lawful attorney-in-fact and agent, with full power of substitution and
         re-substitution, to sign in any and all capacities any and all amendments or post-effective
         amendments to this registration statement, and to sign any and all additional registration
         statements relating to the same offering of securities of the Registration Statement
         that are filed pursuant to Rule 462(b) of the Securities Act, and to file the same with all exhibits thereto and other
         documents in connection therewith with the Securities and Exchange Commission, granting
         such attorney-in-fact and agent full power and authority to do all such other acts
         and execute all such other documents as he may deem necessary or desirable in connection
         with the foregoing, as fully as the undersigned may or could do in person, hereby
         ratifying and confirming all that such attorney-in-fact and agent may lawfully do
         or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this registration statement
         has been signed by the following persons in the capacities and on the dates indicated.
Name
Title
Date
/s/ David E. Lazar
Chief Executive Officer
October 24, 2023
David Lazar
Principal Executive Officer
Chairman of the Board of Directors
Seow Gim Shen
/s/ Katherine Beebe DeVarney, Ph.D.
President, Chief Operating Officer and Director
October 24, 2023
Katherine Beebe DeVarney, Ph.D.
/s/ Avraham Ben-Tzvi, Adv.
Director
October 24, 2023
Avraham Ben-Tzvi, Adv.
Director
Brynner Chiam
/s/ Eric Greenberg
Director
October 24, 2023
Eric Greenberg
/s/ Matthew C. McMurdo, Esq.
Director
October 24, 2023
Matthew C. McMurdo, Esq.
/s/ David Natan
Director
October 24, 2023
David Natan
/s/ Brian Crowley
Vice President, Finance (Principal Accounting Officer)
October 24, 2023
Brian Crowley
17